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Over the years, the study of Natural Killer (NK) cells made it clear that this cells 
are not simply large granular lymphocytes but instead, a highly complex population of 
cells, with versatile characteristics, that can be used in immunotherapy. The expression 
of CD8 by NK cells has not been fully understood but a very important purpose for this 
molecule is believed to exist.  
Peripheral NK cells from healthy individuals, lung cancer patients, chronic 
myeloid leukaemia patients and umbilical cord blood, were characterized by flow 
cytometry according to the expression of CD8. Additional characterization of important 
cell types in the integration of signals between innate and acquired immunity, such as 
ɣδ T cells and Natural Killer T cells as accomplished. 
Here, it was demonstrated that CD8
+
 NK cells may be a more mature and 
cytotoxic subset than their counterparts (showed by the higher expression of CD57 and 
CD7) and that CD8
-
 NK cells seem to be more of a cytokine secretor subset (IL-10 and 
TGFβ). Umbilical cord blood CD8+ NK cells responds to stimuli prompter than their 
equivalents in peripheral blood. Lung cancer patients’ NK cells showed an augmented 
expression of CD57. 
Both CD8
+
 and CD8
-
 subpopulations of CML patients’ iNKT cells reveal 
increased activation when compared to healthy individuals. CD8
+
 iNKT cells are more 
rapidly activated both in lung cancer and in healthy individuals than their CD8
-
 
counterparts. In addition, iNKT cells from lung cancer patients show an increased early 
activation profile than healthy individuals. ɣδ T cells were effectively stimulated by 
Poly (I:C) in order to produce IFN-ɣ in healthy individuals demonstrating the presence 
of Toll-like receptors. 
A similar role for CD8 in NK cells and T cells may be proposed. Further 
elucidation of the role played by CD8
 
in NK cells and others may be a very important 
tool in its application in adoptive cell transfer. 
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Key-words: Natural Killer Cells, CD8
+
 Natural Killer Cells, Innate Immunity, 
cancer, Immunotherapy, Adoptive Cell Transfer. 
Ao longo dos anos tornou-se claro que as células Natural Killer (NK) não 
representam apenas uma população de linfócitos granulares de grandes dimensões, mas 
que se trata de uma população celular extremamente complexa, com varadas 
características, que podem ser usadas em imunoterapia. A expressão de CD8 nas células 
NK não é totalmente compreendida, mas pensa-se que poderá ter um papel muito 
importante na função destas células. 
Células NK de sangue periférico de indivíduos saudáveis, leucemia mielóide 
crónica, cancro do pulmão a sangue do cordão umbilical foram caraterizadas por 
citometria de fluxo de acordo com a expressão de CD8. Uma caraterização suplementar 
de células capazes de integrar de sinais da imunidade inata e adquirida, tal como as 
células T ɣδ e células Natural Killer T (NKT) foi realizada. 
Foi demonstrado que as células NK CD8
+
 poderão ser uma subpopulação mais 
madura e mais citotóxica comparativamente às células NK CD8
-
 (demonstrado pela 
maior expressão de CD57 e CD7). A subpopulação CD8
-
 aparenta ter um maior perfil 
de secreção de citocinas  (IL-10 e TGF-β). As células NK do sangue do cordão 
umbilical CD8
+
 respondem mais rapidamente a estímulos comparativamente aos seus 
equivalentes no sangue periférico. As células NK de cancro do pulmão demonstram 
uma elevada maturidade. 
Ambas as subpopulações de células iNKT CD8
+
 e CD8
-
 de doentes de leucemia 
mielóide crónica demonstraram um perfil de ativação superior ao de indivíduos 
saudáveis. As células iNKT CD8
+
 poderão ser ativadas mais rapidamente em indivíduos 
saudáveis bem como em cancro do pulmão do que as células iNKT CD8
-
. Ainda, as 
células iNKT demonstraram um perfil de ativação prematura em relação a indivíduos 
saudáveis. Estímulos com Poly (I:C) desencadearam a produção de IFN-ɣ pressupondo 
assim, a presença de Toll-like receptors  nas células T ɣδ. 
Um papel semelhante para o CD8 em células NK e linfócitos T pode ser 
proposto. Esclarecimentos adicionais sobre o papel do CD8 nas células NK e noutras, 
pode revelar-se de extrema importância para a aplicação destas em transferência adotiva 
de células. 
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Immune System 
 
The immune system is an extremely versatile defence system that has evolved 
to protect multicellular organisms from pathogens and tumour cells. This system is 
extremely adaptable, defending the body from invaders. The immune system is 
composed of a wide variety of cells and molecules, all working together in a dynamic 
network to recognize and eliminate substances that can cause harm to the organism 
(Figure 1). Besides being able to discriminate between foreign molecules and 
molecules from the body itself, it is also capable of discriminating the body's own cells 
(discrimination self/non-self). The immune system also has the ability to recognize 
altered body cells that can lead to the development of cancer. A more recent definition 
of the immune system is based on the idea of discrimination between what is and what 
is not dangerous for the organism (Moretta and Moretta 2004; Finlay and McFadden 
2006; Vivier, Raulet et al. 2011). 
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The various components of the immune system are able to convert the initial 
recognition event into a variety of effector responses; each response is uniquely suited 
to remove a particular type of pathogen. Although it is simply referred to as the immune 
system, it should be noted that there are two types of immune response: innate and 
acquired (Moretta and Moretta 2004; Caligiuri 2008; Vivier, Raulet et al. 2011). 
Innate Immunity 
 
The innate immune system encompasses molecular and cellular mechanisms that 
help prevent and contain the infection (Finlay and McFadden 2006; Caligiuri 2008; 
Moretta, Locatelli et al. 2008). 
Figure 1 - Cellular constituents of both branches of the immune system (innate and acquired) 
and the cells that may link the two branches of the immune system (Dranoff 2004). 
11 
 
This is the first line of defence, it is highly effective, preventing most early stage 
infections and therefore eliminating them a few hours after initial contact with the 
innate immune system. The innate immune system can precisely distinguish between 
the organism and pathogenic agents, however it is unable to distinguish small 
differences found between the pathogens (Bewick, Yang et al. 2009). 
In Vertebrates, innate immunity is largely dependent on myeloid cells 
(immunocytes that destroy pathogens). In general, these cells are able to carry out their 
functions in isolation but they have evolved to work best in conjunction with cells and 
proteins of the acquired immune system.  The myeloid cells include mononuclear 
phagocytes and polymorphonuclear phagocytes. The mononuclear phagocytes include 
monocytes, macrophages (monocyte-derived) and dendritic cells, all of which have an 
elevated capacity for phagocytosis and play an important role in the presentation of 
antigens to the cells of the acquired immune system. The polymorphonuclear 
phagocytes include the granulocytes: neutrophils, basophils and eosinophils (Chaplin 
2010). 
Another cellular component of innate immunity that is of high importance is the 
Natural Killer (NK) cells. These cells are the only lymphocytic cells belonging to the 
innate immune system. They originate in the bone marrow and are under the influence 
of interleukin-2 (IL-2) and interleukin-15 (IL-15) as well as other bone marrow cells. 
Although they are classified as lymphocytes, these cells do not have receptors for 
specific antigens (Chaplin 2010). 
Even though the cells of the immune system have a limited range of receptors, 
they are still able to recognize many important molecular components found on 
microorganisms, but only if these components do not suffer any mutations. For many 
12 
 
years, Immunologists have focused their study on the capacity of the immune system to 
distinguish between antigens that do not pose a threat from antigens found on hostile 
invaders, recognized by TLRs.  They focused on Pattern Recognition Receptors (PRRs) 
which are able to recognize Pathogen-Associated Microbial Patterns (PAMPs), those 
are molecules associated with groups of pathogens. In addition, Danger-Associated 
Molecular Patterns (DAMPs) (Bianchi 2007) and non-pathogenic Microbial-Associated 
Molecular Patterns (MAMPs) (Pel and Pieterse 2013) are also recognized by PRRs. The 
discovery of Toll-like receptors (TLRs) changed the focus of immunological research. It 
is now known that TLRs have the ability to recognize liposaccharides, glycoproteins 
and nucleic acids and when activated they can trigger a rapid immune response (Beutler 
2004; Bewick, Yang et al. 2009). 
 
Acquired Immunity 
 
The key feature of this type of immunity is focused on its ability, after 
appropriate stimulation, to provide effector capability against a specific antigen and not 
cells, and simultaneously initiate mechanisms that allow a more effective response in 
future infections, even if these infections occur decades later (Chaplin 2010). 
Adaptive immunity exhibits a specific response to a particular pathogen and has 
memory capacity; this memory develops in response to an infection and adapts to 
recognize, eliminate and remember the invading pathogen in case of future encounters 
with the same agent. Adaptive immunity follows innate immunity, starting a few days 
after the initial infection. It provides a complete and a second line of defence, which 
13 
 
eliminates pathogens that escape the innate response or persists despite it. An important 
consequence of an adaptive response is memory. In a second encounter with the same 
pathogen, memory cells provide the mechanism for the adaptive immune system to 
carry out a fast and effective attack against these invading agents (Moretta and Moretta 
2004; Finlay and McFadden 2006; Caligiuri 2008). B and T cells are part of the 
adaptive immune response and express an almost unlimited set of recombinant Ig 
receptors and T-cell receptors (TCR), respectively, which are able to recognize any 
antigen and once activated retain a specific long-term memory (Cooper and Alder 
2006). 
The main characteristics of B and T cells, and consequently the acquired 
immune system, are both its specificity and memory. This specificity allows the 
immune system to recognize subtle differences among antigens. After recognition of a 
specific antigen occurs, B and T memory cells formed by clonal expansion react quicker 
during a second contact than the first interaction (Dempsey, Vaidya et al. 2003). On first 
contact with the antigen, effector B and T cells and memory cells are only able to 
respond after a few days, so it has become clear that the innate immune system is 
essential for limiting or eradicating pathogens during the first phase of infection, i.e. 
before the B and T cells are capable of achieving an efficient response (Moretta and 
Moretta 2004; Finlay and McFadden 2006; David, Morvan et al. 2009; Chaplin 2010). 
 
Innate Lymphoid Cells 
 
Natural killer (NK) cells are an important component of the innate immunity 
and they belong to the family of innate lymphoid cells (ILC) (Montaldo, Vacca et al. 
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2014). Even though some aspects of NK cells remain unclear, it is believed that they 
derive from a common lymphoid progenitor cell type, that later becomes committed 
either to the B, T, dendritic or NK lineage. This common progenitor has been 
identified in human foetal liver, bone marrow and umbilical cord blood (Carayol, 
Robin et al. 1998). Innate lymphoid cells represent a group of cells that share common 
phenotypic and functional characteristics. All ILC have morphological characteristics 
of lymphoid cells, however, they do not have modified antigen receptors, i.e. they lack 
the somatic rearrangement of Ig and T cells receptors, as this is  representative for cells 
of the acquired immune system (Yu, Freud et al. 2013). The ILC respond to a wide 
variety of signals and have important roles in the formation of lymphoid tissue, repair 
damaged tissue, tissue homeostasis and immunity against infectious microorganisms 
and tumours cells. They are thought to be developmentally related once their derive 
from a common precursor expressing the transcription factor ID2 (Spits and Cupedo 
2012; Montaldo, Vacca et al. 2014). 
Although NK cells have been studied for close to four decades, other ILC have 
been better characterized only in the last few years. ILC plays an extremely important 
role not only in innate defence but also in lymphoid tissue organization mainly during 
foetal life. 
There are three different functional groups of ILC (ILC1, ILC2 and ILC3) 
accordingly to the cytokine array that they produce and the transcription factors needed 
for their differentiation. The characteristics of the three groups are summarized in 
Figure 2. 
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Innate Lymphoid Cells type 1 (ILC1) 
The cells belonging to these group are characterized by their ability to produce type 1 
cytokines and that have the ability to eliminate target cells, which includes NK cells 
(other similarities of ILCs and NK cells are represented in Figure 3), and more recently, 
cells that can produce IFN-γ, although it is still not clear if these cells represents a 
different population or a specialized group of NK cells, located in specific tissues 
(Fuchs, Vermi et al. 2013).  
 
 
Innate Lymphoid Cells type 2 (ILC2) 
Limited information is available about ILC2, especially in humans. Cells belonging to 
this subset were originally described as innate helper cells, due to their ability to 
Figure 2 - Developmental liaison between NK cells and other groups of ILC.  
The upper row shows the different stages of human NK cell differentiation process (from left to 
right); the lower row shows ILC2 and ILC3 and the similarities of some immature stages of NK 
cells with other ILCs namely from group 2 and 3. Dashed arrows indicate common phenotypic 
and/or functional properties (also shown in red) (Montaldo, Vacca et al. 2014). 
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produce type 2 cytokines. ILC type 2 are involved in the production of cytokines 
associated with Th2 cells, in particular IL-5 and IL-13 (Spits and Cupedo 2012; 
Montaldo, Vacca et al. 2014). 
 
 
Innate Lymphoid Cells type 3 (ILC3) 
The transcription factor RORγt is a landmark of ILC3 involved in the formation of 
lymphoid tissues that can produce Th17, IL-17 and IL-22 cells. Besides, ILC3 share 
common markers with NK cells such as CD56 and some NCRs (NKp44, and NKp46) 
(Montaldo, Vacca et al. 2014). 
 
 
Figure 3 – Main features of Innate Lymphoid Cells (ILCs), that distinguishes them into three 
different groups (Montaldo, Vacca et al. 2014). 
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Natural Killer cells 
Development and maturation 
 
NK cells originate from Hematopoietic Precursor Cells (HPCs) that are CD34
+
, 
throughout a sequential acquisition of receptors and functions. The commitment of NK 
cells lineage requires not only the expression of specific transcription factors but also an 
appropriate cytokine microenvironment (Carayol, Robin et al. 1998; Freud, Yokohama 
et al. 2006) 
 Nowadays it is clear that NK cell development occurs not only in bone marrow 
but also in peripheral lymphoid and non-lymphoid organs. This findings have mainly 
being achieved by the characterization of the surface expression of some receptors 
namely, CD34, CD117, CD94 and CD56 (Freud, Yokohama et al. 2006) 
In early stages, NK cells were shown to be derived from 
CD34
+
CD45RA
+
CD10
+
cells present in the bone marrow but this type of cells can also 
give rise to T and B cells (Yu, Freud et al. 2013). Further studies have shown that 
peripheral blood have CD34
low
CD45RA
−
CD10
−α4β7hiCD7+/− cells able to further 
differentiate in NK cells (Freud and Caligiuri 2006). 
With this, differentiation stages of NK cells development were described as: 
stage I, as the most immature (CD34
+
CD45RA
+
CD117
−
CD94
−
CD56
−
), stage II and 
stage III as intermediate stages (CD34
+
CD45RA
+
CD117
+
CD161
−/+
CD94
−
CD56
− 
and 
CD34
−
CD117
+
CD161
+
CD94
−
CD56
−/+
, respectively), stage IV or pre-mature 
(CD34
−
CD117
−
CD94
+
CD56
bright
CD16
−
), and stage V, as the most mature state 
(CD34
−
CD117
−
CD94
−/+
CD56
dim
CD16
+
), where the acquisition of functions and 
receptors  (Freud and Caligiuri 2006). NK cells development, beyond occurring in BM 
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is possible in peripheral organs trough a migration of HPCs and/or NK cell committed 
precursors (NKPs) from bone marrow to peripheral locations such as it is believed to 
occur in decidual and endometrial tissues (Di Santo 2006; Montaldo, Vacca et al. 2014). 
 
Functional properties 
 
NK cells are part of the innate immune response, they are morphologically 
characterized as large granular lymphocytes that have cytotoxic activity against tumour 
cells and cells infected by certain types of viruses, they are also involved in autoimmune 
diseases and allogeneic responses (Moretta and Moretta 2004; Yawata, Yawata et al. 
2008). In fact, these effector cells are able to enter and defend the tissues almost 
immediately after infection occurs (Vivier, Raulet et al. 2011). These cells are able to 
recognize normal or aberrant cells through multiple receptors, which detect normal host 
molecules, ligands induced in stressful situations and patterns displayed by pathogenic 
agents. The role of NK cells in the innate immune response appears to be their rapid 
recruitment to sites of inflammation, due to the production of pro-inflammatory 
cytokines and their cytolytic response without prior sensitization (Stewart, Laugier-
Anfossi et al. 2005). 
Recently, new data revealed that these cells may be the link between innate and 
acquired immunity since they have characteristics of both branches of the immune 
system (innate and acquired) exhibiting the ability to develop an antigen- dependent 
memory (Stewart, Laugier-Anfossi et al. 2005; Vivier, Raulet et al. 2011). Moreover, 
due to their interaction with dendritic cells, B cells and T cells, NK cells significantly 
influence the magnitude and quality of the subsequent adaptive response (Moretta and 
Moretta 2004; Stewart, Laugier-Anfossi et al. 2005). NK cells have also come to be 
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recognized as cells that express a repertoire of activating and inhibitory receptors that 
have been calibrated to ensure tolerance of the body's own constituents, while allowing 
a high efficacy against attacks such as viral infections and tumour development as cited 
above (Moretta and Moretta 2004; Stewart, Laugier-Anfossi et al. 2005; Vivier, Raulet 
et al. 2011). 
In humans, NK cells account for about 5-20 % of circulating lymphocytes and 
they are also found in the lymph nodes, spleen and peripheral tissues (Lopez-Verges, 
Milush et al. 2011). Due to the fact that they produce early cytokines and chemokines 
(regulators of inflammatory responses) and for their ability to lyse target cells without 
prior sensitization, NK cells are crucial components of the innate immune system 
(Moretta and Moretta 2004; David, Morvan et al. 2009; Cheng, Zhang et al. 2012). The 
ability of NK cells to readily elicit an immune response is possible, as they are involved 
in the early production of interferon-γ (IFN-γ) required for the control of certain viral, 
bacterial and parasitic infections; and by the production of TNF-α, interleukin-10 (IL-
10) and growth factors (Lanier 1998; Cheng, Zhang et al. 2012). NK cells require two 
signals to produce IFN-γ. One of these signals is always the cytokine IL-12. The second 
signal can be provided by IL-2, IL-15 or IL-18 (Dranoff 2004; De Maria, Bozzano et al. 
2011). 
 
Subpopulations and phenotypes 
 
In humans, the NK cells can be divided into two subsets according to the density 
of CD56 expressed on their surface (glycoprotein expressed on the surface of these 
cells); the first is CD56
bright
CD16
–
 (has a regulatory activity for producing increased 
amounts of cytokines) and the second is CD56
dim
CD16
+
 (exhibit greater cytotoxic 
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activity, although it is now clear that they also are able to produce large amounts of 
cytokines) (Montaldo, Del Zotto et al. 2013). Both groups have different phenotypic 
properties; unique functional attributes and therefore different roles in the immune 
response (Cooper, Fehniger et al. 2001; Yawata, Yawata et al. 2008; Lopez-Verges, 
Milush et al. 2011; Cheng, Zhang et al. 2012; Konjevic, Jurisic et al. 2012). The CD56 
antigen is an isoform of human neuronal adhesion molecule its role in NK cells remains 
unknown although it is thought that it may be involved in the adhesion between this cell 
type and its target cells. The majority of NK cells in humans (about 90 %) are 
CD56
dim
CD16
+
 while only 10% are CD56
bright
CD16
-
 (Cooper, Fehniger et al. 2001). 
Currently, it is known that there is a differential expression of receptors in these 
two subpopulations of NK cells (CD56
bright
CD16
-
 and CD56
dim
CD16
+
). It is believed 
that the differential expression of inhibitory receptors probably provides the ability to 
regulate the cytotoxicity of these cells (Cooper, Fehniger et al. 2001). 
 
More recently new NK cells subpopulation has been described. For example, a 
CD7
+
 NK cell subset was reported. Even though CD7 is also expressed in T cells and 
pre-B cells, the expression of this receptor at the cell surface of NK cells was related to 
the co-expression of NK cell-associated receptors such as KIRs and NCRs and the lack 
of CD7 was related with monocytes/dendritic cells markers such as HLA-DR (Milush, 
Long et al. 2009). Additionally, the expression of CD7 on NK cells was associated to a 
higher cytokine production and cytotoxicity. After stimulation, either with target cells or 
cytokines, the CD7
+ 
NK cell subset showed a greater production of IFN-γ, perforin 
release and CD107a expression, exhibiting increased effector functions (Milush, Long 
et al. 2009). 
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Contrary to cells of the acquired immune system, NK cells lack the antigen-
specific receptors present on B and T cells. CD4 and CD8 are normally expressed in T 
cells playing an important role in assisting in the recognition of MHC molecules, even 
though these receptors can also be expressed in other hematopoietic cells, which is the 
case of NK cells. Despite the fact that CD4 has been largely studied in CD4
+
 T cells, not 
much is known in other cell types. The function of CD4 in NK cells begins to be 
understood (Bernstein, Plasterer et al. 2006). Some studies report that CD4 can 
efficiently mediate NK cells cytotoxicity and that CD4
+
 NK cells are more likely to 
produce cytokines such as IFN-γ and TNF-α (Bernstein, Plasterer et al. 2006). Others 
Figure 4 - Differences in receptor expression between CD56
+
 immune cell subsets. 
 Model depicting the distribution of receptors on (A) CD4
-
 NK cells, (B) CD4
+ 
NK cells, and 
(C) CD56
+
 monocyte/DC-like cells. Receptors expressed on the majority of cells of that subset 
are represented in black. No expression or lower than 15% of cells expressing a receptor is 
indicated in grey (Milush, Long et al. 2009). 
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defend that the function of CD4 in innate cells could be related to FcR-dependent 
responses and suggests a potentiation role for this receptor (Gibbings and Befus 2009). 
In T cells, CD8 has been related to the enhancement of CTL cytokine release 
and cytotoxic activity, due to an amplification of TCR-MHC CLASS I binding 
(Gibbings and Befus 2009). In NK cells particular case, besides the expression of CD56 
and CD16, it has also been described that, in healthy individuals, NK cells express 
about 50% of the CD8 α-homodimer at the cell surface, and that this expression can be 
regulating some NK functions, similar to what occurs with T cells (Spaggiari, Contini et 
al. 2002). 
 
More recently, four novel subsets of NK were identified accordingly to the 
expression of CD11 and CD27 (Figure 3).  The gain and loss of these receptors may 
show a maturation path and distinct functional properties. The double negative NK cells 
display an immature phenotype and a potential for differentiation. This cell population 
was found in large numbers in Umbilical Cord Blood, in line with a more immature 
developmental stage. The double positive population was shown to have the best ability 
to secrete cytokines. Furthermore, single positive CD11b
+
 proved to be highly cytolytic 
(Fu, Wang et al. 2011; Desbois, Rusakiewicz et al. 2012). 
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Moreover, NK cells have been shown to be able to acquire antigen-specific 
memory, an immune adaptive feature, related to the expression of CXCR6, on human 
liver cells. The presence or absence of this receptor create a new subset of NK cells, in 
which CXCR6
+
 NK cells have the ability to respond more effectively to a recall 
challenge, even though the presence of this receptor alone is not sufficient to induce or 
maintain memory (Paust, Gill et al. 2010).  
 
Natural Killer Receptors 
 
NK cells do not rearrange their coding genes for antigen recognition receptors, 
but they have the ability to recognize target cells through activating or inhibitory 
receptors expressed on the cell surface, the Killer Immunoglobulin-like receptors 
(a) (b) (c) (d) (e) 
Figure 5 - Maturation stages of NK cells.  
CD19
−
CD3
−
CD56
+
 NK cells are generally defined by high expression (bright) or 
intermediate (dim) expression of the CD56 molecule. Several studies have been suggesting a 
maturation path according to the expression of CD27 and CD11b. (a) The most immature 
state of NK cells is shown (CD27
-
CD11b
-
). (b) NK cell start their maturation having a low 
expression of CD27 (CD27
low
CD11b
-
). (c) An intermediate maturation state of NK cells 
referred as pre-mature NK cells. (d) Along the maturation, NK cells gain CD11b becoming 
CD27
low
CD11b
low
. (e) At the final stage of maturation NK cells lose CD27 and gain even 
more CD11b, becoming CD27
-
CD11b
+
 (Desbois, Rusakiewicz et al. 2012). 
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(KIRs). The balance between activating and inhibitory signals will determine the level 
of NK cell activation, lysis of the target cell will occur only when activating signals 
prevail in respect of inhibitors (Lanier 2005). The family of KIRs comprise now a total 
of six activating and seven inhibitory receptors, besides KIR2DL4 that can function 
both as inhibitory and activating (Ivarsson, Michaelsson et al. 2014). 
The first point of control is related to the expression the Major 
Histocompatibility Complex  (MHC) class I (Karre, Ljunggren et al. 1986). A low 
expression of MHC class I is observed during tumour transformation and viral infection 
which prevents the binding by inhibitory receptors of the NK cell (Langers, Renoux et 
al. 2012). Simultaneously, ligands for activating receptor have to be expressed in the 
target cell to trigger cytotoxicity by NK cells. These ligands are absent or expressed at 
low levels in normal cells whereas its expression is enhanced in potentially dangerous 
cells (Lanier 2005). 
The mechanism by which NK cells recognize their target cells and their 
subsequent activation or inhibition is still not completely understood. However, it is 
believed that the MHC class I receptors are crucial in this process (Cooper, Fehniger et 
al. 2001). The process by which this mechanism occurs was proposed after the 
observation that NK cells lysed cells containing no MHC class I (Stewart, Laugier-
Anfossi et al. 2005). 
NK cells can eliminate pathogens by different mechanisms of recognition. The 
greatest advances in the understanding the true role of NK cells in the body’s defence 
has been related to the discovery and molecular characterization of numerous surface 
receptors that play a crucial role in the function of these cells (Cheent and Khakoo 
2009). 
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Three mechanisms of recognition by NK cells have been proposed. The "non-
self recognition", "stress induced recognition" and "lack of self-recognition” (Cheng, 
Zhang et al. 2012). 
NK cells recognize MHC class I via surface receptors that transmit signals that 
inhibit (rather than activate) NK cell cytotoxicity (Moretta and Moretta 2004; Ruggeri, 
Mancusi et al. 2005; Yawata, Yawata et al. 2008; Cheng, Zhang et al. 2012). This 
recognition of MHC class I further demonstrates the interaction between the innate and 
adaptive immune system (Stewart, Laugier-Anfossi et al. 2005). 
A key example is represented by the specific immunoglobulin MHC class I 
receptors that plays an important role in the regulation of NK cell function and are also 
involved in the recognition of receptors from subpopulations of NK cells (Moretta, 
Locatelli et al. 2008). Some of the surface receptors involved in the process of MHC 
class I recognition by NK cells are the so-called killer immunoglobulin-like receptors. 
They are expressed by NK cells and a subpopulation of T cells and represent specific 
inhibitory receptors that act on allelic forms of MHC class I, Human Leukocyte Antigen 
(HLA) in humans (Moretta and Moretta 2004; Ruggeri, Mancusi et al. 2005; David, 
Morvan et al. 2009; Purdy and Campbell 2009). After the recognition of HLA class I 
molecules, KIR block the activation of NK cells (Moretta and Moretta 2004; Moretta, 
Locatelli et al. 2011). In the absence of interaction between HLA class I and KIR, 
immediate lysis of the target cell occurs, since the predominant signals in this situation 
are activating signals (Moretta and Moretta 2004; David, Morvan et al. 2009). 
 Various scenarios resulting from the contact between NK cells with other cell 
types may exist. Examples of this are shown in Figure 6. 
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Figure 6 - Representation of the interaction between NK cells and potential target cells and the 
possible outcomes of this meeting according to the receptors present on the surface of potential 
targets.  
In (A) activation of NK cells does not occur since inhibitory signals prevail over activating 
signals. In (B), the loss of MHC class I expression during cellular transformation is responsible 
for a prevalence of activating signals, resulting in NK cells killing of target cell. In (C) an 
increased expression of activating receptors will lead to an higher frequency of activating 
receptors, culminating in lyse of target cell (Vivier, Ugolini et al. 2012). 
 
The lack of interaction between these receptors with MHC class I molecules can 
result in the death of the target cells (Moretta and Moretta 2004; Ruggeri, Mancusi et al. 
2005; Yawata, Yawata et al. 2008). The absence of this interaction occurs when the 
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target cells fail to express or express an insufficient amount of MHC class I molecules, 
which occurs during tumour transformation or infection with certain viruses (Moretta 
and Moretta 2004; Purdy and Campbell 2009; Cheng, Zhang et al. 2012). The various 
immediate reactions carried out by the innate immune system against invading 
pathogens can lead to the end of the infection without needing to involve the acquired 
immune system and without disease manifestation (Moretta and Moretta 2004). 
The only rule that seems to exist with respect to the expression of receptors is 
that all NK cells have, at least, one inhibitory receptor specific for MHC class I 
molecules in order to avoid self-reactivity (Langers, Renoux et al. 2012). Some of the 
receptors present on NK cells are shown in Figure 7. 
In addition to expressing inhibitory and activating KIRs, NK cells also express 
activating receptors that have been well characterized. These include C-type lectins 
(CLEC) and Natural Cytotoxicity Receptors (NCRs) (de Rham, Ferrari-Lacraz et al. 
2007; Cheng, Zhang et al. 2012). 
The main activating receptors involved in cell lysis are CD16, NKG2D and 
NCRs (Bauer, Groh et al. 1999; Bryceson, March et al. 2005; Biassoni 2008). 
 The activating receptors have charged residues in their transmembrane domain, 
which is required for its interaction with adapter proteins. These proteins have small 
extracellular domains and therefore do not participate in the interaction with ligands. 
The adapter proteins have in their intracellular domain docking sites for signalling 
molecules that play an important role in stimulating downstream reactions (Olcese, 
Cambiaggi et al. 1997; Lanier, Corliss et al. 1998). 
The CD16 (low affinity Fc receptor III) has a transmembrane domain and is 
found on the surface of NK cells but also on some dendritic cells, T cells, monocytes 
and macrophages (Moldovan, Galon et al. 1999). When IgG molecules recognize 
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specific antigens on the surface of tumour cells, NK cells, via the CD16 receptor are 
able to bind opsonized tumour cells and trigger processes that will induce tumour cell 
death. This process is known as Antibody-Dependent Cellular Cytotoxicity (ADCC), it 
is dependent on the action of perforin and granzyme molecules, which are capable of 
damaging the cell membrane of the target cell (Nimmerjahn and Ravetch 2007). 
The NKG2D receptor is expressed on most NK cells and is associated with the 
adapter protein DAP10 (in humans) (Rosen, Araki et al. 2004; Champsaur and Lanier 
2010). Ligand binding protein DAP10 and also MICA or MICB lead to an increase in 
proliferation, cytotoxicity and production of cytokines and chemokines (Sutherland, 
Chalupny et al. 2002). 
Major NCRs expressed in NK cells are NKp46, NKp44 and NKp30. They were 
collectively named as NCRs for their ability to strongly activate NK cell cytotoxic activity 
(Sivori, Carlomagno et al. 2014). 
NKp30 and NKp46 are expressed both on resting NK cells as well as in 
activated NK cells, while NKp44 is only expressed on activated NK cells (Cantoni, 
Bottino et al. 1999). The quantity of NCRs expressed on the surface of NK cells differs 
from individual to individual and this level of expression may determine the ability of 
these cells to eliminate tumour cells (Costello, Sivori et al. 2002). 
NKp80 is a particular case. It is virtually expressed by all freshly isolated NK 
cells from peripheral blood and it may function as a co-receptor rather than a classical 
receptor. NKp80 appears to function synergistically to NCRs where it has been 
described that the strength of the activating signal may be reinforce, in part, by NKp80 
(Moretta, Bottino et al. 2001). 
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NKp80 was identified as a dimer, and it is present on the surface of any new or 
activated NK cell. This co-receptor appears to play a key role in certain types of 
pathologies, since their inhibition with monoclonal antibodies triggered partial mediated 
inhibition of NK cell to lyse a type of blastoma, while having no effect on other tumour 
(Vitale, Falco et al. 2001). 
 
 
 
 
 
Figure 7 - Representation of different cell surface receptors expressed by NK cells.  
It is found that there is a differential expression of these receptors in the two NK cell 
subpopulations (NK CD56
bright
CD16
-
 and CD56
dim
CD16
+
) (De Maria, Bozzano et al. 2011). 
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Natural Killer Cells and Cancer 
 
Different mechanisms by which NK cells can eliminate cancer cells are known:  
a) Cytotoxicity mediated by Perforin/Granzyme: 
 The release of cytotoxic granules containing perforin and granzyme is the 
fastest and the most powerful way of eliminating tumour cells. NK cells 
create synapses with their target cells, into which perforin and granzyme are 
released, resulting in the death of target cell (Bryceson, March et al. 2005). 
b) Apoptosis mediated by death receptors: 
 The death of the target cell is induced by apoptosis via ligands from the  
Tumour Necrosis Factor (TNF) family, Fas ligand and Tumour Necrosis 
Factor-Related Apoptosis-Inducing Ligand (TRAIL), an alternative way for 
granule release.  This second mechanism is slower, with duration of a few 
hours, and it is often less effective than the mechanism previously 
mentioned (Takeda, Hayakawa et al. 2001). 
c) Effector functions of Interferon-γ: 
 Upon activation, NK cells secrete various cytokines such as interferon-γ, 
TNF-α, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), 
IL-10 or IL-13 and its anti-tumour activity can be mediated by IFN-γ. In 
fact, this cytokine inhibits tumour cell proliferation in vitro and in vivo it 
indirectly inhibits through the induction of anti-angiogenic factors. It has 
been stated that IFN-γ is capable of enhancing the cytotoxic activity of NK 
cells either by increasing the expression of adhesion molecules, by 
increasing the sensitivity of tumour cells to granule-mediated cytotoxicity or 
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through the involvement of death receptors (Trinchieri 1995; Street, Cretney 
et al. 2001). 
 
 
 
Figure 8 - Mechanism of NK cell effector functions.  
There are three main mechanisms by which NK cells can eliminate the target cells: dependent of 
granules which may be triggered by (a) signalling of activating receptors and secretion of 
granzyme and perforin into the intercellular cleft between NK cell and tumour cell. Perforin 
disturbs the tumour cell membrane which allows the entry of Granzyme, (b) FAS ligand or 
tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) expressed by some NK cells 
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bind to their ligands present at the surface of tumour cells inducing apoptosis of tumour cell, 
and (c) by the secretion of effector molecules such as IFN-ɣ  that can be regulated by Nitric 
Oxide (NO) (Smyth, Hayakawa et al. 2002). 
 
Natural Killer Cells and Infection 
 
Normally, NK cells are associated with an immune response against tumour 
cells and virus-infected cells, however, they may also participate in immune responses 
against bacteria, fungi and protozoa (Culley 2009; Chiche, Forel et al. 2011).  
In the case of infection with the Influenza virus both in animal models and in 
humans, it is possible to see a mobilization of NK cells to the lungs resulting in the 
deletion of these cells culminating in increased mortality only a few days after infection. 
NK cells and adaptive immune response are regulated by each other since NK cells are 
needed for the activation of cytotoxic T lymphocytes and IL-2 production by these 
lymphocytes leads to an increased secretion of IFN-γ by NK cells in subsequent 
responses. The fight against infection involves several receptors. In the specific case of 
the activating receptor NKp46, critical in the protection against lethal infection in mice, 
is one of the few known cases in which there is a direct interaction between viral 
glycoprotein and a NK cell receptor. In addition, there is a possibility of direct 
interaction with TLRs by molecular structures derived from pathogens, such as LPS, 
RNA or DNA. It has also been suggested that the activating receptors NCR may be 
involved, not only in indirect recognition, but also in the recognition of direct structures 
associated with pathogens (Galluzzi, Vacchelli et al. 2012). 
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Invariant Natural Killer T Cells 
 
As with NK cells, invariant Natural Killer T (iNKT) cells are thought to play an 
important role in tumour immunosurveillance and their function is starting to be 
uncovered (Vivier, Ugolini et al. 2012). 
iNKT cells are characterized by the expression of an invariant T cell receptor α chain 
encoded by a Vα24Jα18 rearrangement (iNKT1 cells). They are believed to be the 
optimal tool to an ideal anti-tumour immunotherapy once this cell type is able to make 
the connection between the two branches of the immune system by recognizing α-
galactosylceramide conjugated with CD1d (MHC class I-like), typically expressed by 
APCs and that have the ability to bind a wide variety of lipids, augmenting the immune 
response. Besides the expression of TCR, iNKT cells also express a diversity of 
receptors from both NK and conventional T cells (Monteiro and Graca 2014) Due to 
their  ability to rapidly produce IFN-γ they are able to, in one hand, recruit NK cells 
which will eradicate MHC class I negative tumour cells, and in the other and, recruit T 
CD8 lymphocytes that will eliminate MHC class I positive tumours, that would escape 
NK cells killing, pursuing a complete removal of tumour cells (Figure 9) (Fujii, Shimizu 
et al. 2013). The role of this cell type is not only related to tumour immunosurveillance 
but also with a wide variety of other diseases related to transplantation, allergy, 
autoimmunity and other inflammatory pathologies (Monteiro and Graca 2014). 
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Figure 9- Killing strategies of iNKT cells.  
(a) iNKT cells are able to eliminate CD1d tumour cells by one of two strategies. They can either 
kill directly malignant cells and/or recruit NK cells. (b) Even though some tumour cells do not 
express CD1d, iNKT cells can be indirectly activated by CD1d expressing-Antigen Presenting 
Cells. This will lead to the promotion of NK cells and lysis of the target cell. (Adapted from 
(Vivier, Ugolini et al. 2012). 
 
 
Gamma delta T cells 
 
In healthy adults, γδ T cells represent only about 0.5 to 5% of circulating T cells. 
The importance of this cell type is related to their ability to both share features, 
depending on a particular context, of innate and adaptive systems and they have been 
considered more than a third player in the adaptive system but a third branch of the 
immune system (Hayday 2000). 
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γδ T cells, besides expressing TCR, also express NK cells receptors, as NKG2D 
and heterodimeric complex CD94/NKG2A and increasing evidences reported that they 
may also express TLRs (Barakonyi, Kovacs et al. 2002; Wesch, Beetz et al. 2006). In 
this way, they are able to target stress-induced or infected cells as well as tumour cells 
(Ferreira 2013). With interest, γδ T cells not only have the capability to directly present 
antigens to naïve αβ T cells but they also influence DC maturation by an intensive 
production of TFN-α (Brandes, Willimann et al. 2005; Anderson, Gustafsson et al. 
2012). 
Adoptive Cell Transfer 
 
Immunotherapy is a strategy that uses certain components of the immune system 
to combat diseases such as cancer. This may be achieved in different ways:  
- Stimulation of the immune system itself so that it can more effectively attack 
tumour cells.  
- Administration of immune system constituents, such as proteins from this 
system.  
Immunotherapy includes a variety of treatments that may function differently. 
While some appear to strengthen the immune system indiscriminately, others strengthen 
the immune system so that it becomes more reactive and effective against specific cells 
(Kirkwood, Butterfield et al. 2012). 
Adoptive cell transfer (ACT) involves the (re) introduction of large amounts of 
lymphocytes with anti-tumour activity in a patient. When possible, the starting material 
for ACT is obtained through surgery or a biopsy, from this the infiltrating lymphocytes 
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in tumours are isolated and/or selected for its specificity for TCR. Before the reinfusion 
of lymphocytes, these processes suffer ex vivo expansion in the presence of certain 
interleukins and growth factors so that immunostimulatory compounds may also be 
activated. In situations where the starting material cannot be obtained by surgery or 
biopsy, there is the possibility of using genetic engineering in order to convert 
lymphocytes obtained from peripheral blood into lymphocytes with the ability to 
eliminate malignant cells. In this situation, the lymphocytes are genetically engineered 
so as to express TCRs that recognize antigens of tumour cells with high affinity 
(Parkhurst, Riley et al. 2011). 
Current NK cell-based immunotherapy, aims to overcome the quiescence of 
these cells in patients. One strategy focuses on activation or proliferation of the patient’s 
own NK cells or on the induction of NK cells with greater cytotoxicity. These 
objectives have been met with success in the treatment of certain cancers, by 
administering cytokines and type I interferons. These compounds are involved in the 
differentiation and activation of these cells, being that these cytokines are part of 
interleukins-2, -12, -15, -18 and -21 (Cheng, Zhang et al. 2012). Another strategy uses 
expanded allogeneic NK cells. In this case, allogeneic NK cells are in vivo or ex vivo 
activated or expanded and are not inhibited by self-histocompatibility antigens in the 
way autologous NK cells are. Other approach uses a stable allogeneic NK cell line that 
favours large-scale production. Here, cells are transferred after ex vivo expansion. 
Alternative approaches rely on genetic modification of NK cells or NK cell lines in 
order for them to present an higher expression of cytokines, Fc receptors or chimeric 
tumour-antigen receptors following different approaches, for instance, silencing of 
inhibitory receptors, overexpression of activating receptors or cytokine transgene 
(Cheng, Chen et al. 2013). 
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In addition to the recognition of MHC class I, NK cells also exhibit other forms of 
recognition. Unlike T cells, NK cells do not express specific receptors for antigens; as 
mentioned before, the function of NK cells is mediated by a complex balance of 
activating and inhibitory signals that are recognized by a variety of surface receptors. As 
such, the manipulation of this cell type in order to make them readily reactive against 
tumour cells may be an important tool in combating and eradicating tumours in 
combination with other types of conventional treatments such as chemotherapy 
(Parkhurst, Riley et al. 2011). 
Moreover, it has recently been described that NK cells are required for dendritic cell-
based therapies at the time of tumour challenge. Dendritic cells therapies take advantage 
of their role as APCs. As NK cells tumour destruction can lead to an increased release 
of tumour antigens within the lymphatic system, the antigens presented lead  to an 
induction of T cell response amplifying DC function (Bouwer, Saunderson et al. 2014). 
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Natural Killer cells were dubbed, back in 1975, according to their ability to 
promptly kill cancer cells without prior sensitization (Kiessling, Klein et al. 1975). 
Since then, much has been discovered about this cell type and a great increase in the 
knowledge of NK cells tools has been achieved. NK cells have been described as being 
professional killer cells with license to kill target cells (Nash, Teoh et al. 2014). 
Although, mechanisms by which target cells are able to escape NK killing strategies 
have also arise. In this way, characterization of NK cells subsets besides the classical 
CD56
bright 
and CD56
dim
, that can more efficiently eradicate target cells and/or more 
easily be manipulated in a concerned manner are needed.  
Thus, we propose to characterize subpopulations, phenotypes and functional 
properties in Natural Killer cells that can be useful for immunotherapy. We will focus 
on CD8 subpopulations of NK due to a large expression of this adhesion molecule in 
this cell type and because of the importance of CD8 in the effector functions of 
cytotoxic T lymphocytes. Peripheral blood NK cells from healthy individuals and 
umbilical cord blood will be analysed as NK cells from both cells sources show similar 
characteristics. Further, healthy individuals NK cells will be compared with some 
neoplastic pathologies, such as lung cancer and chronic myeloid leukaemia. In addition, 
important cell types related to the communication among innate and adaptive immune 
system that share common features with NK cells, iNKT and γδ T cells, will be studied, 
also in regard to the expression of CD8.  
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Material and Methods 
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Study Populations 
 
A total of 31 peripheral blood samples from healthy individuals, with ages 
comprised between 18 and 65 years old, were collected in leukocyte depletion bags, 
provided from Instituto Português do Sangue e Transplantação (CST Coimbra).  
Peripheral blood from 4 lung cancer patients and 6 umbilical cord blood were 
included. Lung cancer samples were stabilized for 24h in Transfix® (Caltag, 
Buckingham, UK), a solution that prevents cellular degradation in human and animal 
blood for analytical testing purposes. Additionally, 22 patients of chronic myeloid 
leukemia under tyrosine-kinase inhibitors (TKIs) therapy were studied. All the patients 
were attended at Centro Hospitalar e Universitário de Coimbra. 
 
Blood donors and patients signed informed consent and this study was 
previously approved by the Ethics Committee of Faculdade de Medicina da 
Universidade de Coimbra and Centro Hospitalar e Universitário de Coimbra. 
 
Peripheral Blood Mononuclear Cells (PBMCs) Isolation 
 
The most widely used technique to obtain PBMCs refers to the separation of the 
different cell types present in peripheral blood by density gradient separation, normally 
using  Ficoll-Paque®. Briefly, peripheral blood was diluted 1:3 with PBS 1x EDTA 
0.1mM. Diluted blood was added to a 50 mL Falcon® prepared with 10 mL of Ficoll-
Paque®. The tube was then centrifuged at 400g for 20 minutes at room temperature. 
PBMCs were collected and washed twice with PBS 1X EDTA 0.1 mM. After this, cells 
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were ressuspended in 10 mL of complete medium (RPMI 1640 with glutamax 
supplemented with 10% of heat inactivated Foetal Bovine Serum and 1% of 
Penicillin/Streptomycin) 
 
Cell Counting  
 
After isolation cells were counted in the COULTER AC•T diff Analyzer 
(Beckman Coulter) using 12 μL of leukocytes in complete medium. The method used in 
COULTER AC•T diff Analyzer accurately counts and distinguishes cells by detecting 
and measuring changes in electrical resistance when a particle in a conductive liquid 
passes through a small orifice. 
 
Cell Viability 
 
Trypan blue was used to assess cell viability. This assay rests on the assumption 
that viable cells have intact cell membranes, impermeable to certain dyes, such as 
Trypan Blue, whereas death or senescent cells lose membrane integrity and get stained 
(Strober 2001). To 10 μL of cell suspension were added 10 μL of Trypan Blue (0,2%).  
10 μL were then transferred to a Neubauer chamber and counted in a Leitz microscope.  
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Natural Killer cells Enrichment – Magnetic Activated Cell Sorting  
 
NK cells were isolated from PBMCs using a negative selection magnetic activated cell 
sorting (MACS) Human NK cell Isolation kit (Miltenyi Biotec, Bergisch Gladbach, 
Germany) accordingly to the manufactures instructions. Briefly, cell number was 
determined. According to the desired number of cells, a certain volume of cell 
suspension was centrifuged (10 minutes at 300g) and ressuspended in appropriate 
amount of buffer, 40 μL of MACS buffer (PBS 1x pH 7.2, 0.5% Foetal Bovine Serum 
and 2 mM EDTA) per 10
7 
total cells. 10 µL of Biotin-Antibody cocktail was added per 
10
7 
total cells. Cells were incubated at 4ºC for 5 minutes. 30 µL of MACS buffer was 
added per 10
7 
total cells followed by the addition of 20 µL of Micro Beads per 10
7 
total 
cocktail and incubated at 4ºC for 10 minutes. Cells were then passed onto a depletion 
column whereas the flow through represents the negative portion of the cells suspension 
i.e. NK cells fraction. LS Depletion columns were hydrated previous to use with 3 mL 
of MACS buffer and washed twice with 3 mL of MACS buffer after cell flow through 
of labelled fraction.  
 
In vitro stimulation of PBMCs 
 
In vitro leukocyte stimulation was performed with polyriboinosinic polyribocytidylic 
acid, also know as Poly (I:C), IL-2, IL-12, IL-18, LPS and phorbol 12-myristate 13-
acetate (PMA) and Ionomycin. 1 to 2 million of cells were cultured in 24 well plate for 
24h in complete medium (RPMI 1640 with glutamax plus 10% of foetal calf serum and 
1% antibiotic/antimicotic) supplemented with different stimuli: Poly (I:C) (10 ug/mL), a 
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combination of IL-2, IL-12, IL-18 (100 ng/mL each), LPS (100 ng/mL) and PMA (2.5 
µg/mL) plus Ionomycin (0.5 µg/mL).  
Degranulation assay 
 
1x10
6
 NK cells were co-cultured with target cells (at an effector:target ratio 3:1) 
for 5 hours on 96 well U-bottom plates. 
CD107a was added at the beginning of the experiment. After 1 hour of co-
culture, Brefeldin A was added to the well and the incubation proceeded for 4 hours. At 
the end, cells were harvested and staining with monoclonal antibodies was performed. 
Data acquisition was achieved using BD FACSCanto II.  
 
Surface and Intracellular staining for Flow Cytometry 
  
1 million cells were added to a staining tube. Monoclonal antibodies were added 
following manufacturers recommendations. Cells were then incubated in the dark, at 
room temperature. After that cells were incubated with 2 mL of BD Lysing Solution® 
(for surface staining) or 100 µL Fix and Perm Medium A
®
 (for intracellular staining) for 
10 minutes in the same conditions as previously. Cells were then washed with 2 mL of 
PBS 1x EDTA 0.1 mM and centrifuged at 300g for 5 minutes. Supernatant was 
disposed. For intracellular staining, 100 µL of Fix and Perm Medium B
®
 and at the 
same time intracellular mAbs were added and incubated for 20 minutes in the 
conditions previously described. Cells were washed with PBS 1X EDTA 0.1 mM and 
49 
 
centrifuged at 300g 5 minutes. Cells were ressupendend in 300 µL of PBS 1X and 
acquired in the flow cytometer. 
Table 2- Summary of the monoclonal antibodies reactivities, conjugates and respective 
clones. 
mAb reactivity Conjugate Clone 
CD3 PerCpCy5.5 HIT3a 
CD4 V500 RPA-TA 
CD7 PE CD7-6B7 
CD8 APC HIT8a 
CD14 PerCpCy5.5 M5E2 
CD16 APCCy7 3G8 
CD19 PerCpCy5.5 HIB19 
CD28 FITC CD28.2 
CD56 PeCy7 HCD56 
CD57 PB HCD57 
CD69 PECy7 FN50 
CD107a PE H4A3 
CD137 APC 4B4-1 
CD137L PE 5F4 
TCR Vα24-Jα18 (iNKT cell) PE 6B11 
TCRγδ PE B1 
TGFβ FITC TW4-6H1 
IL-10 PE JES3-9D7 
Granzyme B FITC GB11 
Perforin PB dGg 
 
Flow Cytometry Analysis  
All sample data was acquired in FACSCanto II from BD Biosciences with 
FACS Diva software version 6.1.3. Data from flow cytometry were analysed using 
FlowJo version 10.6 (Tree Star Inc, Ashland, USA). 
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Compounds  
 
The following compounds were used: PBS, RPMI 1640 with Glutamax, Heat 
Inactivated Foetal Bovine Serum, Penicillin, Streptomycin, Fungizone® (amphotericin 
B) (GIBCO, Invitrogen, Carlsbad, CA, USA); Lipopolysaccharide (LPS) and Poly (I:C) 
(InvivoGen, San Diego, CA, USA); All antibodies and human recombinant IL-2, IL-12 
and IL-18 used were purchased from Biolegend (San Jose, CA, USA); PMA and 
Ionomycin (SIGMA-Aldrich St. Louis, MO, USA). 
 
 
Statistical Analysis 
 
Statistical analyses were performed using GraphPad Prism version 5 software. 
Mann-Whitney non-parametric test, One-way ANOVA and Two-Way ANOVA tests 
were used. Tukey’s post-test was performed when needed. Statistically significant P 
values are annotated as follows: * p<0.05, ** p<0.01 and *** p<0.001. 
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Natural Killer cells from Healthy Individuals 
 
In order to elucidate the role of novel NK cells subpopulations, healthy 
individuals were studied and characterized accordingly to the surface expression of CD8 
using Flow Cytometry. Since CD8 in T cells is described to synergistically enhance 
ligation MHC class I-ligand, the presence of CD8 in NK cells might be related to the 
same process. 
First of all, lymphocytes were gated according to their size and complexity by 
Side Scatter (SSC) and Forward Scatter (FSC) parameters (Figure 10). Within this gate, 
NK cells were then selected as CD3/CD14/CD19 negative population. 
 
 
 
 
 
 
 
 
 
 
Figure 10 - Illustration of the gating strategy for Natural Killer cells selection.  
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NK cells show two different subsets related to the expression of CD8 
 
The main focus in the present work was to describe significant differences in NK 
cells that could be useful for the characterization of new subsets, and how these 
differences can be favourable for the use of NK cells in immunotherapy. Here we found 
that the expression of CD8 by NK cells leads to two different subsets and that the 
differences in these subsets are not altered by stimuli (Figure 11). 
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Figure 11 - Analysis of NK cells CD8 expression in Healthy Individuals samples.  
In (A) Non stimulated samples (n=14), (B) stimulated with 10µg/mL Poly (I:C) (n=12), 
(C) stimulated with a cocktail IL-2,IL-12 and IL-18, 100 ng/mL  each (n=12) and (D) 
100 ng/mL lipopolysaccharides (n=12). Cells were incubated for 24h at 37ºC. Cell 
expression of CD8 was assessed by flow cytometry and NK cells were selected as CD3, 
CD 4 and CD19 negative population. Non parametric Mann-Whitney showed consistent 
significance among the four conditions (p<0.001). 
 
Taking in account the results shown in Figure 11, it is possible to admit that the 
expression of CD8 is not affected by different stimuli, being the relative expression 
CD8+/CD8- persistent despite of the stimuli.  
(C) 
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Figure 12 - Analysis of CD8+ subpopulation of NK cells with different stimuli. 
 (A) Non stimulated samples, (B) stimulated with 10 µg/mL Poly (I:C), (C) stimulated with a 
cocktail of IL-2, IL-12 and IL-18, 100 ng/mL  each and (D) 100 ng/mL lipopolysaccharides 
(n=12). Cells were incubated for 24h at 37ºC. Cell expression of CD8 was assessed by flow 
cytometry and NK cells were selected as CD3, CD14 and CD19 negative population. One-way 
ANOVA showed significant differences among the data set (p<0.001) though Tukey’s post-test 
did not reveal significances between each column. 
  
Taking in account the results shown in Figure 12, it is possible to observe slight 
overall differences in the percentage of CD8
+
 NK cells when cells are subjected to 
different stimulus however there are no differences when each stimuli is compared with 
the others. 
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Figure 13 - Analysis of CD8- subpopulation of NK cells with different stimuli in Healthy 
Individuals. 
In (A) Non stimulated samples, (B) stimulated with 10 µg/mL Poly (I:C), (C) stimulated with a 
cocktail IL-2,IL-12 and IL-18, 100 ng/mL  each and (D) 100 ng/mL lipopolysaccharides (n=12). 
Cells were incubated for 24h at 37ºC. Cell expression of CD8 was assessed by flow cytometry 
and NK cells were selected as CD3, CD 4 and CD19 negative population. One-way ANOVA 
showed significant differences among the data set (p<0.001) though Tukey’s post-test did not 
reveal significances between each column. 
 
As it occurs for the CD8
+ 
subset, by the observation of Figure 13, it is possible to 
perceive the same tendency for the CD8- subpopulation. Minor changes are observed in 
the percentage of CD8- NK cells in the presence of different NK cells stimuli. 
 
CD8+ NK cells subset show an higher expression of CD7 
 
The expression of CD7 has been related to the production of effector molecules 
by NK cells (Milush, Long et al. 2009). Therefore, a differential expression in CD8 
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subsets can highlight for their functional role and some of their properties. Also, 
possible differences due to different stimuli were tested.  
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Figure 14 - Analysis of the relative expression of CD7 by CD8
+
 and CD8
- 
NK cells in Healthy 
Individuals. 
Showed in (A) Non stimulated samples, (B) stimulated with 10 µg/mL Poly (I:C), (C) 
stimulated with a cocktail IL-2,IL-12 and IL-18, 100 ng/mL each and (D) 100 ng/mL 
lipopolysaccharides (n=12). Cells were incubated for 24h at 37ºC. Cell expression of CD8/CD7 
was assessed by flow cytometry and NK cells were selected as CD3, CD 4 and CD19 negative 
population. One-way ANOVA showed significant differences among the data set (p<0.001) 
though Tukey’s post-test did not reveal significances between each column. 
 
Regarding Figure 14, it is clear that the CD8
+
 subset has an higher expression of 
CD7 and that this relative expression is not altered when cells undergo different 
conditions. These data suggests that CD8
+
 NK cells might be an effector population. 
 
CD8
+
 NK Cells represent a more mature subset 
 
CD57 expression has been considered as a maturity marker, i.e., as a marker of 
terminal differentiation and possibly a senescence indicator (Sze, Giesajtis et al. 2001). 
Its expression has been reported to increase with age and associated with some clinical 
(D) 
60 
 
conditions. Additionally, new-born NK cells lack this receptor (Nielsen, White et al. 
2013). 
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Figure 15 - Analysis of the relative expression of CD57 by CD8
+
 and CD8
- 
NK cells in Healthy 
Individuals.  
Illustrated in (A) Non stimulated samples, (B) stimulated with 10 µg/mL Poly (I:C), (C) 
stimulated with a cocktail of IL-2, IL-12 and IL-18, 100 ng/mL each and (D) 100 ng/mL 
lipopolysaccharides (n=12). Cells were incubated for 24h at 37ºC. Cell expression of 
CD8/CD57 was assessed by flow cytometry and NK cells were selected as CD3, CD14 and 
CD19 negative population. Non-parametric Mann-Whitney analysis showed consistent 
significances in the expression of CD57 among CD8
+ 
and CD8
-
 NK cells (p<0.01). 
 
From the observation of Figures 15, we are able to say that CD8
+
 NK cells may 
be a more mature subset, and even though the cell stimulation conditions, these stimuli 
were not effective in promote the maturation of the CD8
-
 NK subset. 
 
NK cells regulate the expression of CD137 according to stimuli but express 
few or none CD137L 
 
The targeting of immunomodulatory mAbs to promote anti-tumour activity can 
be the next step in immunotherapy. One example of this strategy might be the use of 
CD137 (4-1BB). CD137 is an inducible T-lymphocyte surface molecule belonging to 
the Tumour Necrosis Factor Family. Its biding to a ligand promotes the co-stimulation 
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of CD4 and CD8 T lymphocytes (Simeone and Ascierto 2012). CD137 is expressed by 
a variety of cells, including NK cells, and it is believed to modulate an adaptive 
response against cancer cells. This molecule can be revealed as an high priority in the 
modulation of T cells using innate cells in immunotherapy (Lin, Liu et al. 2010). 
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Figure 16 – Analysis of the expression of CD137 (A) and CD137L (B) in Healthy Individuals 
NK cells that have undergone different stimuli (Non stimulated samples, stimulated with 10 
µg/mL Poly (I:C), stimulated with a cocktail IL-2, IL-12 and IL-18, 100 ng/mL each and 100 
ng/mL LPS (n=12)). 
(A) (B) 
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Cells were incubated for 24h at 37ºC. Cell expression of CD137/CD137L was assessed by flow 
cytometry and NK cells were selected as CD3, CD14 and CD19 negative population. One-way 
ANOVA revealed significances among the different conditions groups (p<0.01) in (A) whereas 
in (B) no differences were found.  
 
From the observation of Figure 16 it is possible to conclude that the expression 
of CD137 and its ligand may be induce upon stimulation, even though the lack of 
significance for the expression of CD137L, it is shown that an overall change occurs in 
the expression of CD137 and stimuli with LPS seems to be the more effective. 
 
CD8+ NK cells express none or few TGFβ as well as IL-10 
 
 IL-10 and TGFβ, as immunosuppressive cytokines are very important 
immunoregulatory players in a wide range of diseases including cancer. The production 
of these cytokines my lead to a suppression of adaptive immune response or to a skew 
toward a Th2 response, which is significantly less effective in tumour elimination 
(Zagury and Gallo 2004; Cheng, Chen et al. 2013). In this way, understanding the 
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producer population of these molecules will impact therapy strategies.   
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Figure 17 – Median Fluorescence Intensity (MFI) of IL-10 in CD8+ (A) and CD8- (B), in 
Healthy Individuals NK cells that have undergone different stimuli (Non stimulated samples, 
stimulated with 10 µg/mL Poly (I:C), stimulated with a cocktail IL-2, IL-12 and IL-18, 100 
ng/mL each and 100 ng/mL LPS (n=23)).  
Cells were incubated for 24h at 37ºC. Cell expression of CD8 and production of IL-10 was 
assessed by flow cytometry and NK cells were selected as CD3, CD14 and CD19 negative 
population. One-way ANOVA revealed significances among the different conditions groups in 
(B) (p<0.01), whereas in (A) no differences were found.  
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Figure 18 – Median Fluorescence Intensity of TGFβ in CD8+ (A) and CD8- (B) NK cells 
subsets in Healthy Individuals samples that have undergone different stimuli (Non stimulated 
samples, stimulated with 10 µg/mL Poly (I:C), stimulated with a cocktail IL-2, IL-12 and IL-
18, 100 ng/mL each and 100 ng/mL LPS (n=23)).  
Cells were incubated for 24h at 37ºC. Expression of TGFβ was assessed by flow cytometry and 
NK cells were selected as CD3, CD14 and CD19 negative population. One-way ANOVA 
revealed significances among the different conditions groups (p<0.01) in (B) whereas in (A) no 
differences were found. 
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Giving the graphs from Figure 17, CD8
-
 NK cells are able to produce more IL-
10 than CD8
+
 subpopulation. Regarding the production of TGF-β (Figure 18), once 
again, CD8
-
 subset shows a greater production comparatively to their equivalent CD8
+ 
subset. 
The observation of this figure suggests that the CD8
-
 population may have a 
more regulatory function as their equivalent CD8
+
. 
 
 
CD8+ NK cells tend to produce more Granzyme B than CD8- NK cells  
As a cytotoxic granule, Granzyme B is a very important component of the 
killing machinery of NK cells. 
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Figure 19 – Analysis of Granzyme B production by CD8+ (A) and CD8- (B) NK cells when 
subjected to different stimuli (Non stimulated samples, stimulated with 10 µg/mL Poly (I:C), 
stimulated with a cocktail IL-2, IL-12 and IL-18, 100 ng/mL each and 100 ng/mL LPS (n=23)). 
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 Cells were incubated for 24h at 37ºC. Expression of Granzyme B release was assessed by flow 
cytometry and NK cells were selected as CD3, CD14 and CD19 negative population. One-way 
ANOVA revealed no significant differences.  
 
The observation of Figure 19 shows that even there were no statistical 
differences, CD8+ subsets is there more effective regarding to the production of 
Granzyme B. All the stimuli revealed to increase the production of Granzyme B but this 
production is even more effective when cells undergone a stimulus with a cocktail of 
cytokines and with LPS. 
 
Cytotoxicity Assay 
 
In this assay, the effector skills of NK cells were assessed by the labelling of 
effector granules that are released at time of encounter with a target cell. Here, K562 
cell line (Leukaemia cells) was used. 
By the time degranulation occurs, secretory lysosomes are released. The 
lysosome associated membrane protein-1 (LAMP-1 or CD107a) is transported to the 
surface of NK cells. In this way, CD107a antibodies enable the identification of NK 
cells that have undergone activation for degranulation (Aktas, Kucuksezer et al. 2009). 
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Figure 20 – Analysis of NK cells purity after manual Magnetic Isolation from PBMCs (n=13).  
 
NK cells were isolated from PBMCs with a mean purity of 93.9% of total lymphocytes. 
S
po
nt
an
eo
us
 r
el
ea
se
N
on
 S
tim
ul
at
ed
P
ol
y 
I:C
 1
0u
g/
m
l
IL
-2
,1
2,
18
LP
S
P
M
A
-Io
no
m
yc
in
0
20
40
60
80
100
***
***
*
**
***
NK Cells vs K562
CD8+ NK cells
%
 o
f 
C
D
1
0
7
a
 
Figure 21 – Comparison between CD107a spontaneous release by healthy donors NK cells and 
release promoted by the interaction of NK cells with target cells in CD8
+ 
subset when subjected 
to different stimuli (Non stimulated samples, stimulated with 10 µg/mL Poly (I:C), stimulated 
69 
 
with a cocktail IL-2,IL-12 and IL-18, 100 ng/mL each and 100 ng/mL lipopolysaccharides 
PMA-Ionomycin 0.5 µg/mL (n=6)).  
Cells were incubated for 24h at 37ºC. CD107a release was assessed by flow cytometry and NK 
cells were selected as CD3
-
CD56
+
 population. One-way ANOVA revealed significant 
differences among all the groups when compared with PMA-Ionomycin. 
 
In this assay the spontaneous release was assessed (last column of Figure 21). 
Since the spontaneous release was close to zero (~0,31%), this column was unvalued. 
Stimulus with PMA-Ionomycin was used as positive control. 
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Figure 22 – Comparison between CD107a spontaneous release by healthy donors NK cells and 
release promoted by the interaction of NK cells with target cells in CD8
+
 subset when subjected 
to different stimuli (Non stimulated samples, stimulated with 10 µg/mL Poly (I:C), stimulated 
with a cocktail IL-2, IL-12 and IL-18, 100 ng/mL each and 100 ng/mL lipopolysaccharides and 
PMA-Ionomycin 0.5 µg/mL (n=6)).  
Cells were incubated for 24h at 37ºC. CD107a release was assessed by flow cytometry and NK 
cells were selected as CD3
-
CD56
+
 population. One-way ANOVA revealed significances with 
p<0.001 for PMA-Ionomycin vs Non Stimulate and LPS; significances with p<0.01 for PMA-
Ionomycin vs IL-2, IL-12,IL-18 and significances with p<0.05 for PMA-Ionomycin vs Poly 
(I:C) 10µg/ml. 
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By the observation of Figure 22 it is possible to conclude that the stimulus with 
LPS was ineffective in the promotion of cell cytotoxicity, showing a similar effect as 
the unstimulated cells. Stimuli with a cocktail of cytokines and Poly (I:C) revealed to be 
the more effective since they produce more approximate results as the positive control, 
which reveals a potentiated effect.  
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Figure 23 - Comparison between CD107a spontaneous release by healthy donors NK cells and 
release promoted by the interaction of NK cells with target cells in CD8
-
 subset when subjected 
to different stimuli (Non stimulated samples, stimulated with 10 µg/mL Poly (I:C), stimulated 
with a cocktail IL-2, IL-12 and IL-18, 100 ng/mL each and 100ng/mL LPS and PMA-
Ionomycin 0.5 µg/mL  (n=6)). 
 Cells were incubated for 24h at 37ºC. CD107a release was assessed by flow cytometry and NK 
cells were selected as CD3
-
CD56
+
 population. One-way ANOVA revealed differences with 
p<0.01 for PMA-Ionomycin vs Spontaneous Release and LPS and significances with p<0.05 for 
PMA-Ionomycin vs IL-2, IL-12, IL-18. 
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Once again, spontaneous release was assessed for CD8
-
 subpopulation, although 
in this case the spontaneous release was greater (~4.3%) it was still unvalued. 
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Figure 24 - Comparison between CD107a spontaneous release by healthy donors NK cells and 
release promoted by the interaction of NK cells with target cells in CD8
-
 subset when subjected 
to different stimuli (Non stimulated samples, stimulated with 10 µg/mL Poly (I:C), stimulated 
with a cocktail IL-2, IL-12 and IL-18, 100 ng/mL each and 100 ng/mL lipopolysaccharides and 
PMA-Ionomycin 0.5 µg/mL (n=6)).  
Cells were incubated for 24h at 37ºC. CD107a release was assessed by flow cytometry and NK 
cells were selected as CD3
-
CD56
+
 population. One-way ANOVA revealed differences with 
p<0.01 for PMA-Ionomycin vs LPS and significances with p<0.05 for PMA-Ionomycin vs IL-2, 
IL-12, IL-18 and Non Stimulated. 
 
In Figure 24 it is possible to comprehend that CD8
-
 cells do not respond as effectively 
to stimuli, in particular to LPS, that shows the higher statistical difference 
comparatively to PMA-Ionomycin (Positive Control).  
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Figure 25 – Comparison of CD107a release in the two CD8 subsets of NK cells exposed to 
different stimuli (Non stimulated samples, stimulated with 10 µg/mL Poly (I:C), stimulated with 
a cocktail IL-2,IL-12 and IL-18, 100 ng/mL each and 100 ng/mL lipopolysaccharides and PMA-
Ionomycin 0.5 µg/mL (n=6)). 
 Cells were incubated for 24h at 37ºC. CD107a release was assessed by flow cytometry and NK 
cells were selected as CD3
-
CD56
+
 population. Two-way ANOVA revealed no differences 
within the different groups.  
 
Comparing the percentage of CD107a labelling, once more CD8
+ 
NK cells 
revealed, although not statistically significant, a greater labelling than their equivalent 
CD8
-
, being the stimuli with Poly (I:C) and the cocktail of cytokines the most 
effectives. 
As mentioned before, NK cells recognize and kill virus-infected and/or transformed 
cells, through two main pathways, being one of them the release of cytotoxic granules 
to the surface of target cells (Cullen, Brunet et al. 2010). In this way, Granzyme B and 
Perforin production, as NK cells cytotoxic granules, was evaluated.  
73 
 
     
 
NK Cells vs K562
+ - + - + - + - + -
0
1
2
3
4
5
Non Stimulated
Poly I:C 10ug/ml
IL-2,IL-12,IL-18
LPS
PMA-Ionomycin
ns
CD8 NK cells
%
 o
f 
G
rz
B
 r
e
le
a
s
e
 
 
NK Cells vs K562
+ - + - + - + - + -
0
20
40
60
80
100
Non Stimulated
Poly I:C 10ug/ml
IL-2,IL-12,IL-18
LPS
PMA-Ionomycin
ns
CD8 NK cells
%
 o
f 
P
e
rf
 r
e
le
a
s
e
 
Figure 26 – Analysis of Granzyme B (A) and Perforin (B) release by CD8+ and CD8- healthy 
donors NK cells with different stimuli (Non stimulated samples, stimulated with 10 µg/mL Poly 
(I:C), stimulated with a cocktail IL-2,IL-12 and IL-18, 100 ng/mL each and 100 ng/mL 
lipopolysaccharides and PMA-Ionomycin 0.5 µg/mL  (n=2)).  
Cells were incubated for 24h at 37ºC. CD107a release was assessed by flow cytometry and NK 
cells were selected as CD3
-
CD56
+
 population. Two-way ANOVA revealed no differences 
within the different groups. 
(A) 
(B) 
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By the observation of Figure 26, it is possible to determine that the majority of 
the released granules are Perforin granules and that this release is higher in CD8
+
, 
although sample size is reduced and additional assays are essential. 
 
Stimuli with cytokines is the more effective in promoting IFN-γ production 
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Figure 27 - Analysis of Interferon-γ production by CD8+ (A) and CD8- (B) NK cells when 
subjected to different stimuli (Non stimulated samples, stimulated with 10 µg/mL Poly (I:C), 
stimulated with a cocktail IL-2,IL-12 and IL-18, 100 ng/mL each and 100 ng/mL 
lipopolysaccharides and PMA-Ionomycin 0.5 µg/mL  (n=4)). 
 Cells were incubated for 24h at 37ºC. The expression Interferon-γ production was assessed by 
flow cytometry and NK cells were selected as CD3
-
CD56
+
 population. One-way ANOVA 
revealed in (A) significant values for Non Stimulated vs IL-2, IL-12, IL-18 (p<0.01), IL-2, IL-
12, IL-18 vs LPS (p<0.01) and LPS vs PMA-Ionomycin (p<0.01). In (B) p<0.01 values were 
found for 10µg/mL Poly (I:C) vs IL-2, IL-12, IL-18 and 10µg/mL Poly (I:C) vs PMA-
Ionomycin ; p<0.001 values were found for Non Stimulated vs IL-2, IL-12, IL-18; IL-2, IL-12, 
IL-18 vs LPS and IL-2, IL-12, IL-18 vs PMA-Ionomycin 0.5µg/mL. 
 
Observing Figure 27 it is possible to assess that there are significant differences 
among the outcome regarding IFN-γ production with different stimuli but no differences 
were found regarding the comparison between the CD8
+
 and CD8
-
 subpopulations of NK cells 
being both effective in the secretion of this cytokine, mainly when stimulated with a 
combination of IL-2, IL-12 and IL-18. 
 
Umbilical Cord Blood NK cells 
 
The phenotypic characteristics of NK cells from umbilical cord blood and 
peripheral blood are similar. Cells from both sources reveal analogous percentages of 
bright and dim subpopulations (Dalle, Menezes et al. 2005) but some other features, 
such as the expression of some NK receptors, for instance CD94, NKp46 and NKG2D 
differ (Verneris and Miller 2009). 
The use of umbilical cord blood hematopoietic stem cells has revealed itself in a 
very exciting approach and many progresses have occurred in recent years (Oran and 
Shpall 2012). The use of cord blood have shown a growing interest since it includes a 
rapid availability and less HLA matching requirements among other advantages 
(Verneris and Miller 2009).  
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Figure 28 – Analysis of NK cells percentage among Healthy donors (n=7) and Umbilical Cord 
Blood (n=5).  
Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 
and CD19 negative population. Non-parametric Mann-Whitney test was performed showing 
that the two groups are significantly different (p<0.05).  
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Figure 29 - Analysis of CD8
+
 NK cells percentage among Healthy donors (n=7) and Umbilical 
Cord Blood (n=5).  
Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 
and CD19 negative population. Non-parametric Mann-Whitney test was performed showing no 
significant differences.  
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The expression of CD8 in cord blood appears to be influenced by stimuli 
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Figure 30 – Comparison of CD8+ (A) and CD8- (B) NK cells percentages in Umbilical Cord 
Blood when subjected to different stimuli (Non stimulated samples, stimulated with 10 µg/mL 
Poly (I:C), stimulated with a cocktail IL-2,IL-12 and IL-18, 100 ng/mL each and 100 ng/mL 
lipopolysaccharides and PMA-Ionomycin 0.5 µg/mL  (n=6)). 
 Cells were incubated for 4h at 37ºC. The expression CD8 was assessed by flow cytometry and 
NK cells were selected as CD3
-
CD14 and CD19 negative population. One-way ANOVA 
revealed in (A) significant values for Non Stimulated PMA-Ionomycin (p<0.05), IL-2, IL-12, 
(A) 
(B) 
78 
 
IL-18 vs PMA-Ionomycin (p<0.05) and LPS vs PMA-Ionomycin (p<0.05). In (B) p<0.05 values 
were found for Non Stimulated PMA-Ionomycin; IL-2, IL-12, IL-18 vs PMA-Ionomycin and 
LPS vs PMA-Ionomycin. 
From the observation of Figure 30 it is possible to perceive that the relative 
expression of CD8 is altered when cells undergo different conditions, for instance, 
CD8
+
 subpopulation is diminished, and consequently, CD8
- 
is augmented upon stimulus 
with PMA-Ionomycin 
 
Umbilical Cord Blood NK cells may undergo maturation in vitro 
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Figure 31– Analysis of the expression of CD57 in (A) CD8+ NK cells and (B) CD8- NK cells  
in Healthy Individuals (n=14) and Umbilical Cord Blood (n=4).  
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Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 and 
CD19 negative population. Non-parametric Mann-Whitney test was performed showing that the 
two groups are significantly different (p<0.01) for both CD8
+
 and CD8
-
. 
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Figure 32 – Analysis of the expression of CD57 by CD8+ (A) and CD8- (B) NK cells in 
Umbilical Cord Blood when subjected to different stimuli (Non stimulated samples, stimulated 
with 10 µg/mL Poly (I:C), stimulated with a cocktail IL-2, IL-12 and IL-18, 100 ng/mL each 
and 100 ng/mL lipopolysaccharides and PMA-Ionomycin 0.5 µg/mL  (n=6)).  
Cells were incubated for 4h at 37ºC. The expression CD8 and CD57 was assessed by flow 
cytometry and NK cells were selected as CD3
-
CD14 and CD19 negative population. One-way 
ANOVA revealed in (A) significant overall differences (p<0.05), whereas in (B) no differences 
were found. 
 
An overall maturation is apparent when cells undergo stimulus with PMA-
Ionomycin even though in not statistically significant way for CD8
-
 subset. Also in 
CD8
+
 subset an increase in maturity is perceived, where although data is not 
significantly different in each condition, an overall significance occurs. 
Umbilical Cord Blood cells are expected to be irresponsive to stimuli and to do 
not produce cytokines. 
 
Umbilical Cord Blood NK cells produce few or none IL-10 upon stimulation 
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Figure 33 – Comparison of IL-10 production by CD8+ and CD8- NK cells from Umbilical Cord 
Blood after stimulation (Non stimulated samples, stimulated with 10 µg/mL Poly (I:C), 
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stimulated with a cocktail IL-2, IL-12 and IL-18, 100 ng/mL each and 100 ng/mL LPS and 
PMA-Ionomycin 0.5 µg/mL (n=6)). 
Cells were incubated for 4h at 37ºC. The expression CD8 was assessed by flow cytometry and 
NK cells were selected as CD3, CD14 and CD19 negative population. Two-way ANOVA 
revealed no significant differences among the conditions. 
 
There were no significant differences among the several groups compared, of 
note that even though, when there is production of IL-10, CD8
-
 NK cells produce more 
IL-10 than CD8
+
 with the exception of stimuli with Poly (I:C) 10 µg/mL and PMA-
Ionomycin which may imply that this subpopulation respond more promptly than their 
equivalent. 
 
Chronic Myeloid Leukaemia NK cells 
 
There is a wide array of NK cell dysfunctions reported in cancer. They include a 
decreased cytotoxic activity, down-regulation of activating receptors, poor proliferation, 
decreased cell count and defective cytokine production (Sabry and Lowdell 2013). 
Another reason to explain cancer spread is related to ability of some tumour cells to 
escape NK cells immunosurveillance wherein, in a first phase, tumour cells induce NK 
cell-tolerance and in a second phase they build up a microenvironment favourable to 
their development (Kiessling, Wasserman et al. 1999).   
Chronic Myeloid Leukaemia (CML) is a haematological disorder resulting from 
the clonal expansion of pluripotent hematopoietic progenitors containing the active 
fusion gene BCR/ABL. This mutation displays a constitutive expression of tyrosine 
kinase activity conferring growth, proliferation and resistance to apoptosis advantages 
on leukemic cells. 
82 
 
NK cell frequency is increased in CML 
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Figure 34 – Comparison among the percentage of NK cells in Healthy Individuals (n=25) and 
Chronic Myeloid Leukaemia (n=22). 
 Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 
and CD19 negative population. Non-parametric Mann-Whitney test was performed showing 
that the two groups are significantly different (p<0.05).  
 
CD8 expression by NK cells is similar in health individuals and CML 
patients 
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Figure 35 – Comparison among the percentage of CD8+ NK cells in Healthy Individuals (n=25) 
and Chronic Myeloid Leukaemia patients (n=22). 
83 
 
 Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 
and CD19 negative population. Non-parametric Mann-Whitney test was performed showing no 
differences between the two groups.  
 
It is possible to observe a significant alteration on NK cells numbers among 
healthy individuals and CML patients whereas oncologic patients exhibit an increase on 
NK cells percentage (Figure 34) although no differences are observed regarding the 
percentage of CD8
+
 NK cells (Figure 35). 
 
CML CD8
+ 
NK cells show an increased expression of CD7 
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Figure 36 – Comparison of the percentage of NK cells CD8+CD7+ (A) and CD8-CD7+ among 
Healthy Individuals (n=25) and Chronic Myeloid Leukaemia patients (n=22). 
(A) 
(B) 
84 
 
 Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 and 
CD19 negative population. Non-parametric Mann-Whitney test was completed showing that the 
two groups are not significantly different. 
 
 
No differences in the expression of CD7 were observed in CD8- NK cells 
however CD8+ NK cells from CML patients appear to be augmented when compared to 
healthy individuals. 
 
CML NK cells do not show increased maturity 
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Figure 37 – Comparison of the percentage of NK cells CD8+CD57+ (A) and CD8-CD57+ among 
Healthy Individuals (n=25) and Chronic Myeloid Leukaemia patients (n=22). 
 Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 and 
CD19 negative population. Non-parametric Mann-Whitney test was completed showing that the 
two groups are not significantly different. 
 
Interestingly, the expression of CD57, a maturation marker, reveals that NK 
cells from CML patients and healthy individuals seem to be at a similar developmental 
stage, assuming very analogous levels of CD57. 
 
Lung Cancer NK cells 
 
As mentioned before, numerous alterations on NK cells can be listed on 
oncologic disorders. The opportunity to study NK cells in lung cancer patients allow the 
comparison of CD8 NK cells subpopulations and can represent a great value as NK 
cells rather than T lymphocytes are thought to constitute the main immunological 
barrier to the development of lung cancer (Chang, Lin et al. 2013).   
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Lung Cancer patients show an increase of NK cell frequency 
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Figure 38 – Comparison among the percentage of NK cells in Healthy Individuals (n=7) and 
Lung Cancer patients (n=4). 
 Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 
and CD19 negative population. Non-parametric Mann-Whitney test was performed showing 
that the two groups are significantly different (p<0.05).  
 
As shown above in Figure 38, lung cancer patients exhibit a significant increase 
in NK cell frequency when compared to healthy individuals.  
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Figure 39 – Comparison among the percentage of CD8+ NK cells in Healthy Individuals (n=7) 
and Lung Cancer patients (n=4). 
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 Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 
and CD19 negative population. Non-parametric Mann-Whitney test was performed showing 
that the two groups are significantly different (p<0.05).  
 
No significant alterations are found in the expression of CD7 in NK cell from 
lung cancer patients 
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Figure 40 – Comparison of the percentage of NK cells CD8+CD7+ (A) and CD8-CD7+ among 
Healthy Individuals (n=14), Lung Cancer (n=4). 
 Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 and 
CD19 negative population. Non-parametric Mann-Whitney test was completed showing that the 
two groups are not significantly different. 
(B) 
(A) 
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Once the expression of CD7 is greater in CD8
+
 NK cells in healthy individuals, a 
comparison with the equivalent population in lung cancer appears imperative. As shown 
in Figure 40, lung cancer patients do not exhibit any changes in the expression of CD7. 
In this way, it is possible to admit that their capacity of secreting effector molecules is 
not affected. 
. 
Lung Cancer patients have accumulation of end-stage NK cells 
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Figure 41– Analysis of the expression of CD57 in (A) CD8+ NK cells and (B) CD8- NK cells  
in Healthy Individuals (n=14) and Lung Cancer patients (n=4).  
Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 and 
CD19 negative population. Non-parametric Mann-Whitney test was performed showing that the 
two groups are significantly different (p<0.01) for CD8
+
 subpopulation and (p<0.05) for CD8
-
 
subpopulation. 
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Figure 42– Analysis of the expression of CD57 in CD8+ and CD8- NK cells in Lung Cancer 
patients (n=4).  
Flow cytometry analysis was performed and NK cells were selected as the CD3, CD14 and 
CD19 negative population. Non-parametric Mann-Whitney test was performed showing that the 
two groups are not significantly different. 
 
Comparing Figure 42 with Figure 15, we are able to affirm that both NK cells 
subpopulations from lung cancer patients are consider mature, opposed to what is 
observed in healthy individuals, where CD8
- 
subpopulation express much less CD57 
compared to its equivalent CD8
+
. 
Seeing the results shown in Figure 38 and 41, it is possible to say that Lung 
Cancer patients have an abnormal high number of NK cells, comparatively to healthy 
individuals although they have an high amount of CD57 in both the CD8 subsets 
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revealing that even though lung cancer patients have high numbers of NK cells, they 
belong to a very mature state which in accordance to results shown above, seem to have 
a more regulatory than effector function. 
 
Invariant Natural Killer T cells and γδ T cells 
 
As mentioned before, iNKT and ɣδ T cells are thought to be cells that are able to 
link innate and adaptive immunity, besides that fact, they are also able to inhibit tumour 
progression and development. Whereas iNKT achieve this task in a MHC class I 
dependent manner (Terabe and Berzofsky 2014), while ɣδ T cells achieve do not require 
the conventional help of MHC class I. These cells share common functional and 
phonotypical features of both innate and acquired immune system (Gogoi and 
Chiplunkar 2013; Wang and Welte 2013). For that reason, a characterization of these 
cell types as the one performed for NK cells may help in the understanding of their 
contributions in the elimination of malignancies. 
iNKT cells in healthy donors and oncologic patients (CML and lung cancer) 
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Figure 43 – Comparison of iNKT cells percentage among Healthy Individuals (n=7), Cord 
Blood (n=6), Chronic Myeloid Leukaemia (n=17) and Lung cancer (n=4).  
The expression of TCR Vα24-Jα18 (iNKT) was assessed by flow cytometry and iNKT cells 
were selected as the CD3
+ TCRVα24-Jα18+ population. One-way ANOVA revealed no 
significant differences among cord blood and Healthy Individuals whereas significance was 
found among cord blood and CML and among CML and lung cancer (p<0.001). Overall 
differences in data were found (p<0.01). 
 
A significant difference is shown in iNKT cell frequency among cord blood and CML 
patients and among CML patients and lung cancer patients. Cord blood and lung cancer 
patients show a decreased frequency in this cell type that may imply a deficit in 
communication between innate and acquired immune branches. 
 
Lung cancer patients show impaired expression of CD8 in iNKT cells 
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Figure 44 – Comparison of CD8+ iNKT cells in Healthy Individuals (n=14), Chronic Myeloid 
Leukaemia (n=17) and Lung cancer (n=4). 
The expression of CD8 was assessed by flow cytometry and iNKT cells were selected as the 
TCR Vα24-Jα18 (iNKT cell) and CD3 positive population. One-way ANOVA revealed 
significant differences among CML and lung cancer (p<0.05). 
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Figure 45 – Comparison of CD69 expression among Healthy Individuals (n=14), Chronic 
Myeloid Leukaemia (n=17) and Lung cancer (n=4) in CD8
+
 (A) and CD8
-
 (B) subpopulations. 
The expression of CD69 was assessed by flow cytometry and iNKT cells were selected as the 
TCR Vα24-Jα18 (INKT cell) and CD3 positive population. Non-parametric Mann-Whitney test 
was performed, revealing no significant differences in (A) among Healthy Individuals and CML 
patients (p<0.05) and in (B) among Healthy Individuals and CML patients (p<0.001) and among 
CML and lung cancer patients (p<0.05). For CD8
+
 subset, overall differences among data was 
found (p<0.05) 
 
(B) 
(A) 
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Similarly to the expression on healthy individuals, CD8
+ 
subpopulation in lung 
cancer patients, show a greater expression of this early activation marker (Figure 45 A) 
in comparison with its equivalent CD8
-
 counterpart (Figure 45 B). In regard to CML 
patients, it is possible to detect that both CD8 subsets show an increased activation 
relatively to healthy individuals. 
 
γδ T cells in healthy donors and oncologic patients (CML and lung cancer) 
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Figure 46 – Comparison of γδ T cells percentage among Healthy Individuals (n=17), Cord 
Blood (n=6), Chronic Myeloid Leukaemia (n=17) and Lung cancer (n=4).  
The expression of TCR γδ was assessed by flow cytometry and γδ T cells were selected as the 
TCR γδ positive population. One-way ANOVA revealed significant differences among Healthy 
Individuals and CML patients (p<0.01), among cord blood and CML patients (p<0.05) and 
among CML patients and lung cancer patients (p<0.05). Overall differences among samples 
were found (p<0.001).  
 
A diminished presence of this cell type (<10%) is in accordance with previously 
described (Gogoi and Chiplunkar 2013). Alterations in γδ T cells counts were observed 
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in CML patients. Whereas healthy individuals, cord blood and lung cancer patients 
show similar percentage of TCRɣδ cells, CML patients exhibit differences with these 
three groups.  
H
ea
lth
y 
C
on
tr
ol
s
C
or
d 
B
lo
od
C
M
L
Lu
ng
 C
an
ce
r
0
10
20
30
40
50
CD8+ TCRgd cells
%
 o
f 
C
D
8
+
***
**
**
 
Figure 47 – Comparison of CD8+ γδ T cells percentage among Healthy Individuals (n=17), 
Cord Blood (n=6), Chronic Myeloid Leukaemia (n=17) and Lung cancer (n=4).  
The expression of TCR γδ was assessed by flow cytometry and γδ T cells were selected as the 
TCR γδ positive population. One-way ANOVA revealed no significant the three groups. 
 
Surprisingly, no CD8 was present in TCRɣδ in cord blood. Besides this 
observation, no differences were observed in the remaining groups analysed.  
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Figure 48 – Comparison of IFN-γ production by γδ T cells in Healthy Individuals (n=6) and 
Chronic Myeloid Leukaemia (n=12). 
The expression of IFN-γ was assessed by flow cytometry and γδ T cells were selected as the 
TCR γδ positive population. One-way ANOVA revealed significant differences (p<0.05) among 
non-stimulated cells and cells that were stimulated with Poly (I:C) 10 µg/mL and a cocktail of 
IL-1, IL-12 and IL-18. 
 
γδ T cells are known to be able to produce abundant proinflammatory cytokines such as 
IFN-γ. The same was observed in the present data and most of the production was 
observed when cells undergone stimuli with Poly (I:C) and a combination of cytokines.  
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Increased IFN-ɣ production upon stimulation of γδ T cells with Poly (I:C) 
and a cocktail of cytokines 
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Figure 49 – Comparison of IFN-γ production by γδ T cells in Healthy Individuals (n=6). 
The expression of IFN-γ was assessed by flow cytometry and γδ T cells were selected as the 
TCR γδ positive population. One-way ANOVA revealed significant differences (p<0.05) among 
non-stimulated cells and cells that were stimulated with Poly (I:C) 10 µg/mL and a cocktail of 
IL-1, IL-12 and IL-18. 
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Since the discovery of NK cells in 1975, and their first identification as effector 
cells, important insights of their biology and function have been achieved. It is now 
clear that NK cells are not only CD3
-
CD56
+
 large granular lymphocytes, but they are a 
much more complex population composed by a variety of subpopulations (48 distinct 
subsets identified by (Jonges, Albertsson et al. 2001) besides CD56
bright 
and CD56
dim 
 
and with distinct functions and characteristics even though many of them are still poorly 
described (Cooper, Fehniger et al. 2001; Cheng, Chen et al. 2013). 
From early it was reported that changes in NK cells, such as decreased or absent 
NK cell numbers or changes in its activity, are related to development or progression of 
cancer, chronic infection, autoimmune diseases and immunodeficiency (Shereck, 
Satwani et al. 2007). 
Although NK cells have the ability to kill tumour and infected cells without prior 
sensitization, its target cells have evolved in a way to escape NK cells killing 
mechanisms (Orange and Ballas 2006) either by the tumour microenvironment 
cytokines and chemokines or by the down-regulation of activating receptors as a 
consequence of diverse mechanisms (Moretta, Pietra et al. 2014). The characterization 
of novel subpopulations might overcome some of the difficulties faced with the use of 
NK cells in immunotherapy.  
Very few studies have been described the expression of CD8 in NK cells. It is 
known that only αα-homodimer is expressed by this cell type and that the expression of 
this molecule is presumed to have fundamental significance in NK cells role (Addison, 
North et al. 2005). One of the assumptions that can be made is the correlation of the 
presence of CD8 in NK cells with the function that this molecule has in T cytotoxic 
lymphocytes as an adjuvant of T cell-MHC ligation. As the expression of CD8 by NK 
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cells is approximately 40% (Figure 11), following this thought, only 40% of NK cells 
would have effector functions whereas the remaining 60% would have a more 
regulatory behaviour. In one way, this might explain some of the prevalence of cancer 
cells over NK cells but in the other way, as it was described by Jonges et. al, the 
expression of CD8 by CD56
bright
 and CD56
dim
 NK cells do not differ significantly. Once 
CD56
dim
 NK cells represent about 90% (far above 40% of CD8
+
) of total NK cells in 
peripheral blood, and this subset show cytotoxic functions, this may lead to the question 
of what is expressed by CD8
+
 NK cells that would increase their cytotoxicity 
comparatively to their equivalent CD8
-
. Another interesting finding relay on the 
observation, by (Fuchshuber and Lotzova 1992), that not only the oncolytic activity of 
these two subsets is different but also, that this may be tumour dependent, i.e., 
depending on the tumour phenotype, one or another CD8 subset may be the most 
effective. Interestingly, the expression of CD8 by NK cells is not altered by any of the 
stimuli used in this work (Figures 12 and 13) being observed only slight changes in its 
percentage. This may imply that NK cells maintain their profile over time. 
The expression of CD7 is one of the first signals of differentiation of 
hematopoietic progenitor’s commitment to NK cell lineage. Even more, CD7 is 
believed to play an important role in cell adhesion and activation. It correlates with 
increased cloning efficiency, increased sensitivity to low doses of IL-2 and decreased 
requirement for stromal contact and increased expression of IL2Rβ (Miller, Alley et al. 
1994; Yoo, Kim et al. 2009). Also, this molecule is expressed in both normal mature 
and immature NK cells and changes in the expression of CD7 were associated with 
some diseases (Yoo, Kim et al. 2009). Taking these characteristics in account, an higher 
expression of CD7 by CD8
+
 NK cells (Figure 14) may explain the reason why this 
subset of cells are more effective than their counterparts.  
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The expression of the markers previously discussed only enable the assessment 
of NK cells functional properties, but not on their maturation stage.   
CD57 was initially described as marker for NK cells with poor proliferative 
capacity and probably with some degree of immunosenescence (Brenchley, Karandikar 
et al. 2003). Later, this theory was revisited and instead of an annergy state, it was 
described that the gain of CD57 is part of the natural process of maturation (Lopez-
Verges, Milush et al. 2010). In fact, acquisition of CD57 has been demonstrated to be a 
shift towards increased cytotoxicity, greater responsiveness to CD16 signalling and 
NCRs and decreased sensitivity to cytokines (Lopez-Verges, Milush et al. 2010). Going 
back to the classical bright and dim NK cells subsets, the bright population is more 
immature and immunoregulatory whereas the dim population, is more mature and 
cytotoxic following a similar path of maturation as the previously described for CD57. 
In this way, we can assume that a higher expression of CD57 by CD8
+
 NK cells (Figure 
15), in accordance to the greater expression of CD7 may reveals a more mature and a 
more effective population of NK cells. A more mature state does not mean idling but 
instead, a more accurate path to the final gold: killing the target cell.  
In sum, CD8
+
 NK cells appear to show a greater capacity of effector molecules 
secretion (expression of CD7) and increased cytotoxicity (CD57).  
Transforming growth factor β (TGF-β), a cytokine secreted as a latent complex 
or in its active form, may influence immune cells (Wahl, Hunt et al. 1987). TGF-β is 
one of the first players present at the site of inflammation and has for long been 
established as a tumour promoter at sites of lesion. It is frequently produced by cancer 
cells to establish a favourable microenvironment, inhibiting NK and T cells 
immunosurveillance (Medina-Echeverz, Fioravanti et al. 2014). More recently, a biased 
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role for this cytokine was proposed where dysregulations on TGF-β pathways are 
related with poor prognosis outcome in some cancers (Akhurst and Derynck 2001). NK 
cells appear to be the main lymphocyte population to produce substantial amounts of 
TGF-β regulating adaptive response by influence of T regulatory cells (Horwitz, Gray et 
al. 1999). Relatively to the present work, it is possible to observe that CD8
-
 NK cells are 
the main TGF-β producer (Figure 18), with overall differences among the different 
stimuli used. Noting that also CD8
+
 NK cells show some production of TGF-β even 
though in a much lower manner. It has been reported that NK cells can both produce 
active and latent TGF-β (Horwitz, Gray et al. 1999), it is possible that a more mature 
subset of NK cells preferentially produces active TGF-β (reducing the amount of total 
TGF-β produced) or even that both isoforms are produced, but since CD8+ subset 
appears to be more mature, the production of cytokines is no longer a priority.   
In its turn, IL-10, produced by both immune innate and adaptive cells, is 
described in most of the studies as having a suppressive role. Nevertheless, this cytokine 
plays a different role in NK cells. In vitro, IL-10 augments NK cells proliferation, 
cytotoxicity, and IFN-ɣ production (Cai, Kastelein et al. 1999; Mocellin, Panelli et al. 
2004). A regulatory subset of NK cells has been described as IL-10 producing cells 
(Deniz, Erten et al. 2008). The major IL-10 producing NK cells subpopulation 
characterized here were CD8
-
 NK cells (Figure 17). Once again, in concordance with 
data shown above, a possible regulatory part for CD8
-
 NK cells is characterized by the 
increased expression of TGF-β and IL-10 and diminished expression of CD57 and CD7. 
Another key factor in the characterization of CD8 NK cells relays on their ability 
to promote anti-tumour immunity.  
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CD137, formerly known as 4-1BB, a protein related with progressive immunity, 
was originally discovered on activated T-cells but has now been described in a variety 
of other cells, including NK cells. It belongs to the family of Tumour Necrosis Factor 
Receptor (TNFR) and its activation on NK cells can augment IFN-ɣ production, 
promoting in this way a T CD8 response (Watts 2005). In the present study, the 
expression of CD137 appears to be modulated by the selected stimuli (Figure 16 A). 
Constitutive expression of CD137 was described in cytokine activated NK cells (Watts 
2005). Interestingly, LPS and Poly (I:C) present similar effects from those of cytokines. 
In this way, it is possible to admit that TLRs triggers also promote a constitutive 
expression of CD137 in NK cells. This observation also demonstrates a link between 
NK cells and T cells. As this receptor is a co-stimulatory molecule of T cells and it is 
up-regulated on innate cells (NK cells), this receptor comprises a link among the two 
branches of the immune system in the way that NK cells and T cells act in a concerted 
manner. Regarding on the expression of CD137L, although no significant differences 
were shown (Figure 16 B), a minor increased is visible in cytokines and LPS activated 
NK cells compared to non-stimulated NK cells. The mechanism by which CD137 and 
its ligand cooperate is not fully understood, but it is believed that receptor-ligand 
interaction occurs via APCs (Watts 2005) therefore, a minor CD137 expression on NK 
cells (less than 0.15 % of NK cells) may be in accordance with this theory.   
Analysis of intratumoural NK cells and their comparison with NK cells from 
other locations have shown that the tumour microenvironment influences biological 
modifications in NK cells (Gillard-Bocquet, Caer et al. 2013). Consequently, exploring 
NK cells changes in these patients can enlighten possible therapeutic strategies. 
Granzyme and perforin are the main elements of the killing machinery of NK 
cells. Granzymes, a family of serine proteases found in cytotoxic T lymphocytes and 
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NK cells (Susanto, Trapani et al. 2012) and a pore-forming, Perforin, responsible for a 
granule-mediated cell death pathway (Voskoboinik, Dunstone et al. 2010). Granzyme 
was assessed in two different preparations in the present work. The first approach 
assessed Granzyme B release by NK cells under different stimulation conditions of 
PBMCs (Figure 19) and when purified NK cells were stimulated (Figure 26). It was 
possible to observe that besides no statistical differences were observed in non-purified 
NK cells, there is an apparent greater release of Granzyme B by CD8
+
 NK cells while 
purified NK cells do not show a similar behaviour. Of note that none of these results are 
significant, therefore only some assumptions can be made. One of the possible 
assumptions is that other cells may signal NK cells in a way for them to produce 
indistinguishably Granzyme B while isolated NK cells do not receive those signals. 
Another assumption is related to the quantity of Granzyme B that is secreted. Where 
NK cells show a greater secretion of this granule when isolated (Figure 26), NK cells 
from PBMCs do not show an equivalent secretion (Figure 19) 
NK cells cytotoxic capacity was evaluated on purified NK cells against K562 
cell line. It is possible to perceive that the most effective stimuli are the cocktail of 
cytokines and Poly (I:C) since they are the two conditions with less statistical 
significance when compared with the positive control for both CD8
+
 (Figure 22) and 
CD8
-
 NK cells (Figure 23) even though the percentage of CD107a release is distinct 
among the two subpopulations, no statistical differences were achieved. The same 
occurs with Perforin and Granzyme B (Figure 26) were no significant alterations are 
noted even though slight modifications can be observed among CD8
- 
and CD8
+ 
as 
supported by previous experiments by (Addison, North et al. 2005). The main NK cell–
mediated killing mechanisms is via perforin and Granzyme but there are no 
significances among CD8
+ 
and CD8
-
 NK cells as well as with, no differences were 
106 
 
found among the two subpopulations and the same behaviour is detected for IFNɣ 
secretion. 
It has been shown that resting umbilical cord blood mononuclear cells have less 
cytotoxicity (Tanaka, Kai et al. 2003) than PBMCs but upon stimulation they are able to 
trigger similar responses as equally treated PBMCs (Nomura, Takada et al. 2001). 
In a more effective way than peripheral blood NK cells, that only show overall 
differences on the expression of CD8 when stimulated (Figure 11), umbilical cord blood 
NK cells respond more promptly showing differences among the different stimuli 
(Figure 30) presumably by a more rapid response to stimuli than peripheral blood NK 
cells.   
An in vitro maturation of umbilical cord blood NK cells may be achieved 
according to data shown in Figure 32 (A), which combined with the increase of CD8 
expression and relating these results with others discussed above, CD8
+
 cord blood NK 
cells may have a more cytotoxic function, similarly to their equivalents in peripheral 
blood but with a greater response in what regards the time needed for that response to 
occur.  
Umbilical cord blood cells are thought to have a low cytokine secretion profile 
but it is believed that upon stimulation they are able to rapidly respond (Kaminski, 
Kadereit et al. 2003), although, no significant changes were achieved in regard to IL-10 
production among the two new NK cells subpopulations proposed in this work (Figure 
33). Further investigation on cytotoxic granules and cytokine profile is needed.  
Alterations among cell populations within disease are common. Few changes in 
cell number in CML and lung cancer patients (Figure 34 and Figure 38) and cell 
phenotype for lung cancer patients (Figure 39) were identified. For instance, in lung 
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cancer patients an exacerbated number of NK cells were found and the discovery of an 
abnormal maturity state of these cells may explain the theory of a constant activation of 
NK cells, due to the presence of tumour cells, leads to a push toward maturation which 
is possibly a more cytotoxic state. In the case of CML patients, no differences were 
identified either in the expression of neither CD8 nor CD57 (Figure 35 and 37), thus 
besides and increase in number, these cells appear to be normal. This fact can be 
explained by a disease control with tyrosine-kinase inhibitors. The only phenotypic 
alteration in these patients was related to an improved expression of CD7 by CD8
+
 NK 
cell subpopulation. As discussed above, CD7 is believed to be related to an increased 
cytotoxicity revealing that in this pathology, CD8
+
 NK cells may play an even more 
cytotoxic effect than the same subset in healthy individuals.  
iNKT cells have been suggested to play an important role in immunoregulation 
(Bendelac, Rivera et al. 1997). In fact, NK properties and cytokine-profile production 
has been demonstrated for iNKT cells (Kitamura, Iwakabe et al. 1999).  
Among the samples studied, none of them show significant differences in regard to the 
percentage of iNKT cells when compared with healthy individuals or either in the 
expression of CD8 by this cell type (Figure 43 and 44). 
CD69 has been demonstrated to be rapidly induced in the surface of activated 
lymphocytes (Risso, Smilovich et al. 1991). Regarding the data obtained (Figure 45), it 
is possible to postulate that CD8
+
 iNKT cells are the subpopulation that appears to be 
more efficiently activated since a higher expression of CD69 is recorded. The 
expression of this early activator marker was increased in CML patients in comparison 
to healthy individuals, whereas no differences were found for lung cancer patients. 
CD69 was found to be up regulated by the expression of the fusion gene BCR-ABL and 
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down-regulated by the suppression of BCR-ABL in CML (Hantschel, Gstoettenbauer et 
al. 2008). Thus the increased expression of this marker in CML comparatively to 
healthy individuals and lung cancer presented in this work are in accordance with the 
expectations. It has been shown that the activation of iNKT cells leads to the activation 
of both innate and acquired immune cells (Nishimura, Kitamura et al. 2000). In this 
way, it is possible to say that the communication between innate and acquired immune 
system, via iNKT cells is not affected in lung cancer patients and it might be over-
activated in CML patients.  
Recent evidences suggest that TLRs are expressed by ɣδ T cells (Wesch, Beetz et al. 
2006). In fact, stimuli with Poly (I:C), an agonist of TLR3, has revealed itself as 
powerful as a cocktail of cytokines in regard to IFN-ɣ production in comparison with 
non-stimulated cells (Figure 48). Still, no significant differences were found in response 
to LPS. The present data suggest that some TLR are expressed by ɣδ T cells.  
IFN-ɣ affects the proliferation of hematopoietic stem cells and affects colony formation. 
In addition, IFN-ɣ genotype has been reported to be related with the response to 
treatment in CML. The presence of mutations in IFNG gene affecting its pathway, 
showed to be the most significant alteration in the prediction of cytogenetic remission 
(Kim, Kong et al. 2010). Data shown in Figure 49 identify a clear difference in IFN-ɣ 
production by ɣδ T cells from CML patients relatively to healthy individuals. Further 
studies having in view the IFNG genetic profile may clarify the reason for such a high 
production of IFN-ɣ. 
A more detailed study of iNKT and ɣδ T cells would be of great value, increasing the 
understanding of their role in NK cells function as well as possible advantages in the 
conjugation of these different cell types.  
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The present work aimed to understand how the presence or absence of CD8 in 
NK cells may influence their functions and how these differentiated functions can be 
useful for immunotherapy.  
Hence, we demonstrated that CD8
+
 NK cells may be an innately a more mature and 
cytotoxic subset than their counterparts (showed by the higher expression of CD57 and 
CD7) and that CD8
-
 NK cells seem to be more of a cytokine secretor subset (IL-10 and 
TGFβ). We also demonstrate that upon cultivation with target cells, both subpopulations 
are able to produce similar amounts of IFN-ɣ, Granzyme B and Perforin, were only 
minor differences can be envisioned. Since CD8
-
 NK cells do not acquire CD57 or CD7 
upon stimulation, a different mechanism by which this subpopulation acquire 
cytotoxicity when co-cultured with target cells may be involved. The expression CD137 
by NK cells was successfully modulated by the stimuli used in this work. 
As CD8
+
 NK cells appear to be more innately cytotoxic than their counterparts, a 
similar role for CD8 in NK cells and T cells may be proposed. We suggest that this 
adhesion molecule play an important role in NK cell ligation to target cell, activation 
and cytotoxicity by enhancing cell to cell contact.  
Umbilical cord blood CD8
+
 NK cells respond to stimuli prompter than their 
equivalents in peripheral blood. CD8
+
 iNK T cells are more rapidly activated both in 
lung cancer and in healthy individuals than CD8
-
 cells. In addition, iNKT cells in lung 
cancer show an increased early activation profile than healthy individuals.  
In lung cancer patients, NK cells were characterized by an augmented 
expression of CD57. It is possible to assume that an excessive activation due to the 
presence of tumour cells may lead to a push toward maturation of NK cells. 
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Natural killer cells from Chronic Myeloid Leukaemia patients do not show 
differences in the expression of CD8 nor CD57. The only change detected was related 
to an increased expression of CD7 by the CD8
+
 subpopulations of NK cells. 
The expression of CD8 by iNKT cells in CML and lung cancer patients was 
similar to healthy individuals. Both subpopulations of NK reveal increased activation 
when compared to healthy individuals. 
ɣδ T cells were effectively stimulated by Poly (I:C) in order to produce IFN-ɣ in 
healthy individuals. The production of this cytokine by non-stimulated ɣδ T cells from 
CML patients showed to be augmented. 
In order to evaluate the exact function of CD8 in NK cells, we expect, in a first 
approach, to block CD8 receptor on NK cells and assess the functional properties of this 
cells in comparison with CD8
-
 NK cells. Additionally, we intend to transduce CD8 into 
CD8
- 
NK cells and evaluate the acquisition or not of CD8
+
 cells functions. A 
51
Cr 
release assay, were CD8 subpopulations of NK would be assessed separately may 
highlight their distinctive functions. 
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